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Preface 
The PreMed project is motivated by the increasing possibilities to exploit data resources in 
providing better health and social care. Data resources are opening the way to precision 
medicine, referring to customization of healthcare to the individual patient. Precision medicine 
opens business opportunities to companies operating especially in pharma and healthcare 
domains. Disease prevention is a growing application area of precision medicine and offers 
opportunities to companies developing products for personal wellness. It is clear that co-
operation of all stakeholders including companies and public organisations is needed in order 
to fully exploit the potential of data-driven precision medicine.  
This report includes the results of the first phase (1.5.2017-31.8.2018) of the PreMed project 
financed jointly by Business Finland and VTT. In order to built an overall understanding of the 
environment a series of stakeholder interviews and a review of precision medicine related 
activities at international scale has been carried out.  Based on the results, opportunities for  
Artificial Intelligence technology in data-driven precision medicine have been identified and 
business opportunities have been analysed. Finally, applying system dynamics approach an 
initial ecosystem model has been build. The model has been used in preliminary simulation of 
ecosystem development scenarios. 
The authors wish to thank the external experts for their contributions by participating the 
interviews and informal discussions and by commenting the draft version of the report. The 
inputs have been essential for completing the report.  
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1 Introduction 
Personal data is increasingly collected and used in the context of digitalized services. 
Consequently, the amount of personal data stored in information systems is increasing 
exponentially. Besides the primary purpose, collected personal data is used for so called 
secondary purposes, such as for monitoring the quality of provided services, in the 
development of new services or products and for scientific research. In general, secondary 
use is permitted under certain conditions by the existing privacy legislation, in particular the 
General Data Protection Regulation (GDPR). Additionally, specific legislation addressing 
secondary use of health data (e.g. in the context of biobanks) has been implemented in some 
countries, including Finland1,2.  
In healthcare, exploitation of data enables precision medicine3, referring to customization of 
healthcare, with medical decisions, treatments, practices, or products tailored to the individual 
patient. This is expected to be cost effective in comparison to the prevailing "one-size-fits-all  
approach" as interventions can be targeted to those individuals, who really benefit from them. 
Precision medicine is often based on genetic, molecular and cellular analysis of the individual 
and involves techniques such as molecular diagnostics, genetic sequencing, imaging and data 
analytics. Precision medicine is increasingly data-driven by integrating multi-omics data, 
clinical data and other real-world data influencing the health or the disease state of the  
individual. 
Precision medicine is expected to have a remarkable role especially in cancer care as tumours 
have particular genetic signatures correlating with their response to treatments. Genetic tests 
can help to decide which treatments a patient's tumour is most likely to respond to, sparing the 
patient from receiving treatments that are not likely to help. Benefits are foreseen also in other 
clinical domains. Metabolomics of certain drugs has been shown to depend on certain gene 
variants, which means that information of these variants can be used when selecting the drug 
to be used in a particular case. Furthermore, the personal risk of many common diseases, 
including many cancers and cardiovascular diseases as well as autoimmune diseases, 
depends on the genome. Knowing these risks through genetic tests is helpful in identifying and 
motivating individuals to preventive interventions. 
Data-driven precision medicine applications in healthcare and pharma domains are based on 
sophisticated analysis of data and increasingly exploiting Artificial Intelligence (AI) 
technologies. Examples in healthcare include advanced data-driven Clinical Decision Support 
systems (CDSS), automation of customer service processes by chatbots and support of self-
care by automatic feedback to patients.       
For the pharmaceutical product development data-driven precision medicine opens new 
opportunities in several phases of drug development. In the preclinical phase genome and 
other individual level data provides understanding of disease mechanisms and helps in 
identifying the drug targets and molecules. The availability of individual-level health data is 
highly valuable for the clinical trials and for Real World Evidence (RWE) studies. 
The recently started FinnGen project4 is expected to have a big positive impact on precision 
medicine in growing a national reserve of genome data and in developing the required 
infrastructure and competences needed to exploit it. In the framework of the project bio 
samples of 500 000 Finns will be collected and combined  with clinical registry data. The data 
and samples will be made available to biobank research during and after the project.      
                                               
1 https://media.sitra.fi/julkaisut/Muut/International_review_secondary_use_health_data.pdf 
2 https://www.biopankki.fi/en/laws-and-regulation/ 
3 https://en.wikipedia.org/wiki/Precision_medicine 
4 https://www.finngen.fi/ 
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Precision medicine has a remarkable business potential. The PreMed project (Business 
ecosystem for Finnish precision medicine platform) is targeted towards identifying and 
increasing the business opportunities for companies based on data-driven precision medicine. 
In particular, the project aims to create an ecosystem model describing how various types of 
companies and public organizations can co-operate and make business.  
This report includes the results of the first year of the PreMed project financed jointly by 
Business Finland and VTT. In order to built an overall understanding of the environment a 
series of stakeholder interviews and a review of precision medicine related activities at 
international scale has been carried out. Based on the results, opportunities for AI technology 
in data-driven precision medicine have been identified and potential business strategies have 
been analysed. Finally, applying system dynamics approach an initial ecosystem model has 
been build. The model has been used in preliminary simulation of ecosystem development 
scenarios.  
The report forms the basis for further work to be carried out in the PreMed project scheduled 
to be completed by April 2020. The detailed plan for further work will be compiled in co-
operation with participating companies. Participation is open to all interested stakeholders 
whether or not they were involved in the project during the first year.           
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2 Scope and definitions 
‘Precision medicine’ is a broad term and lacks a clear and stabilized definition1. It is often used 
interchangeably with ‘personalized medicine’ (Nimmesgern et al. 2017). The scope of the 
report is data-driven precision medicine, which emphasizes the role of individual-level health 
data in increasing our understanding of human health and behaviour as a whole and thereby 
opening new opportunities for new products and services. In particular, we will look at the 
opportunities offered by secondary use2 referring to applications where data is used beyond 
its primary purpose (Danciu 2014). We especially look at secondary use enabled by public, 
centralized data sources.  
The use of biobank materials and data is in this report considered to fall to the secondary use 
domain. Even if samples and data are in many cases collected specifically for the purpose of 
biobank research, still a substantial part of the collections originate from normal healthcare 
processes and are transferred to biobanks for further (secondary) use.           
In this report, we consider widely the exploitation of any kind of health and wellness related 
data - including both clinical and non-clinical data. For example, a person's use of social 
services provides useful information related to holistic wellbeing of the individual. For practical 
reasons we have used the term health data to refer to any health related data. Our main focus 
is in exploiting individual-level data as opposed to population-level aggregated data.   
 
 
                                               
1 https://ghr.nlm.nih.gov/primer/precisionmedicine/precisionvspersonalized 
2 Deloitte: International review on the secondary use of health and social care data and applicable 
legislation 
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3 Health data exploitation infrastructure 
The Finnish infrastructure related to secondary use of health data is depicted in Figure 1. The 
figure shows data sources on the left and data users on the right. In between, centralized data 
storages and services support collection of data and making it available for data users. 
Components of the infrastructure are further described in the sections below.      
 
Figure 1.  Finnish health data exploitation infrastructure  
 
3.1 Primary data sources  
The main data sources shown in the left side of Figure 1 fall into four main groups. Patient and 
customer registers refer to EHR's (Electronic Health Records) and other operational 
information resources used in the provision of health and social care services. Other online 
services refer for example to wellness applications, which are not part of the healthcare 
system, but independently used by the individual. Research registers are collected for the 
purposes of various types of research studies. Depending on the obtained user consent, 
research registers may be maintained beyond their use in the original study and can be used 
later for other studies. Biobanks collect bio samples and related clinical information under the 
Biobank Act1 for the purpose of clinical and population research.   
3.2 Centralized data storages  
Centralized data storages combine information from local and regional systems. Kanta 
services2 include a national EHR archive, which enables accessibility to patient data and social 
care customer data by multiple organisations under consent by the individual and as needed 
in service processes (Hyppönen 2015). All healthcare service providers are required by 
                                               
1 http://www.finlex.fi/en/laki/kaannokset/2012/en20120688 
2 https://www.kanta.fi/en/system-developers/kanta-architecture 
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legislation1 to connect their EHR systems to the Kanta archive and to transfer patient data to 
the archive for all healthcare service events. Besides healthcare, gradually, also social 
services events will be covered by the Kanta system2. Kanta also includes a service (MyKanta) 
which allows citizens to view their own clinical data, provide their consent to share documents 
between registrars, view data usage logs and set restrictions on data usage. MyKanta is 
currently being extended in functionality to also support insertion of own health data manually 
or via personal devices. This functionality is supported by an open API (application 
programming interface), which allows certified applications to be connected with MyKanta and 
to exchange personal health data under consent of the individual. 
Another centralized data storage will be the genome database, which is to be operated by the 
national Genome Center3 currently in preparation.  When ready, the genome database will 
provide a secure storage location for all genome data. This will considerably improve the 
availability of genome data both for healthcare processes and for research purposes.  
National statistical registers collect data needed essentially for statistics and research (Gissler 
2004). Many of the registers are based on national legislation. These registers are hosted by: 
 National Institute for Health and Welfare (THL) 
 The Social Insurance Institution of Finland (Kela) 
 Population Register Centre (VRK) 
 Finnish Medicines Agency (Fimea) 
 Finnish Institute of Occupational Health (FIOH) 
 Statistics Finland 
 Tax Administration 
 
THL maintains several registers needed for providing statistics on the Finnish healthcare 
systems. For example, the Care Register for Healthcare collects data on the activities of health 
centres, hospitals and other institutions providing inpatient care and on the clients treated in 
them as well as on home-nursing clients for the purposes of statistics, research and planning. 
Kela maintains several registers e.g. with information on the use of social benefits and 
purchase of reimbursed medicines. VRK maintains the population information system 
containing basic information (e.g. name, date of birth, native language, address and family 
relation) of Finnish citizens and foreign citizens residing permanently in Finland. Fimea 
maintains registers with information on medicines and their consumption. FIOH maintains 
registers on biological and carcinogenic exposure as well as  several research registers with 
data on occupational health and wellbeing. Statistics Finland provides a wide range of 
statistics and information services. In health research domain, e.g. the Causes of death register 
is widely used. The Tax administration maintains for example the National Incomes Register. 
3.3 Centralized services  
Centralised services for supporting secondary use of data are emerging rapidly. Especially 
important will be the Service Operator, which  aims to be a one-stop-shop where health data 
can be accessed and used in a secure environment. The operator is planned to maintain all 
related service processes and components, including:  
                                               
1 https://www.finlex.fi/fi/laki/ajantasa/2007/20070159 (in Finnish) 
2 https://www.kanta.fi/en/professionals/client-data-archive-for-social-welfare-services 
3 http://stm.fi/en/artikkeli/-/asset_publisher/genomikeskuksen-perustaminen-etenee-tyoryhman-
arviomuistio-lausunnoille 
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 Authentication and authorization 
 Data search and discovery 
 Data access application and acceptance processes 
 Secure, remote data processing environment 
 User support 
 
The Service Operator concept was initially developed in the framework of Sitra's (The Finnish 
Innovation Fund)1 Isaacus project (Section 3.6). The Service Operator activity will be enabled 
by a new law in preparation (Section 3.4.3). The law defines THL as the legal authority 
responsible for accepting data access applications as well as organizing the set-up and 
maintenance of the Service Operator processes. The operative function of the Service 
Operator is estimated by THL to start by the end of 2019, but the schedule is still not confirmed 
and depends on the timing of the Secondary Use Act coming into effect.  
The Finnish biobank co-operative (FINBB) created in 2017 is aimed at providing a single 
channel to the Finnish biobank resources2. The organisation currently has an on-going project 
for developing an availability database, which enables biobank customers to find information 
about available biobank resources. FINBB also provides legal, commercial  and 
communication support for its members.  
3.4 Legislation  
The use of health and social services data is governed by several national laws and EU 
regulation. Complete description of this legislative framework is outside the scope of this report. 
Below, we have briefly described the main legislation from the point of view of secondary use 
of health data.  
3.4.1 General Data Protection Directive  
The General Data Protection Regulation (GDPR) (EU) 2016/679 is a regulation in EU law on 
data protection and privacy for all individuals within the European Union. The GDPR 
substantially increases the obligations of data controllers in ensuring the privacy of data 
subjects. While increasing obligations to data controllers the GDPR also extends the 
opportunities for secondary use of data. The lawfulness of data processing for secondary 
purposes without explicit consent is based on Article 6 (paragraph 1, point e): 'processing is 
necessary for the performance of a task carried out in the public interest or in the exercise of 
official authority vested in the controller'. Article 9 limits the use of 'special categories of 
personal data' such as data concerning health, but enables the use of data for various 
secondary purposes. These include management of health and social care systems and 
services, public health, ensuring healthcare and medicinal products or medical devices, 
archiving, statistical purposes and scientific or historical research. Usage of data for such 
purposes is subject to several measures to be taken by the data processor to protect the data 
subject's privacy and rights.  
The GDPR recital 159 includes a statement that 'scientific research' should be interpreted in a 
'broad manner', including 'for example technological development and demonstration, 
fundamental research, applied research and privately funded research', as well as 'studies 
conducted in the public interest in the area of public health'. This definition enlarges the 
potential for data exploitation. The Finnish Personal Data Act (523/1999) contains provisions 
for usage of data in scientific research and statistics, but not for 'technological development 
and demonstration'.   
                                               
1 https://www.sitra.fi/en/ 
2 https://finbb.fi/ (in Finnish) 
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Besides direct impact on data exploitation, the GDPR may also have indirect favourable 
effects. It strengthens the data subject's rights to obtain copies of his/her own data from the 
data controller. In particular, the data controller shall provide data for the individual in 
'commonly used electronic form' (GDPR/article 15). This will considerably increase the 
possibility for the individual to reuse personal data and to share it with trusted parties, e.g. to 
support research and development activities.    
3.4.2 Finnish national privacy legislation  
The Personal Data Act (523/1999)1 nationally implements the regulation outlined in the EU 
Data Protection Directive (Directive 95/46/EC). Since May 2018 the GDPR has been the 
primary privacy legislation in all EU countries. However, national supplements to the GDPR 
will be allowed. For Finland, such complementary regulation is currently being processed by 
the Parliament of Finland2 and is expected to be in force during autumn 2018. As relevant for 
secondary use of health data, the government's bill for new privacy legislation complements 
the GDPR concerning legal basis of using personal data and the specific requirements 
pertaining to the use of data for scientific and statistical research.  
3.4.3 Legislation on secondary use of health and wellness data   
This law, referred in this report as Secondary Use Act, regulates the use of health and wellness 
data for secondary purposes3. It is currently in the acceptance process by the Parliament of 
Finland. As currently estimated, the Secondary Use Act will be in force by the end of 2018. It 
is closely related to the Biobank Act, but addresses essentially data resources instead of 
biological samples. The objective of the Secondary Use Act  is to enable efficient and controlled 
access of data resources for legitimate exploitation, while maintaining the rights and privacy of 
the data subject. A central component of the law addresses the legal entity which will be in 
charge of granting access to data for data users and of establishing and running the related 
processes. According to the bill the legal entity is the National Institute of Health and Welfare 
(THL), which may outsource the operational processes to be managed by an external 
organization, referred in this report as the Service Operator.      
According to the Secondary Use Act specific consent from the data subject will not be 
mandatory when the data is used for scientific or statistical research, which enables the 
traditional 'registry based research' approach. Usage of data for technical development and 
innovation will be  enabled by the law only under specific consent by the data subject or in 
case the data set is fully anonymised. The legislation does not explicitly define the concepts 
'scientific research' and 'technical development and innovation'. Consequently, the judgement 
of the categorisation will need to be made case-by-case by the respective data controller.      
3.4.4 Biobank Act  
The Finnish Biobank Act entered into force in 2013.  The act provides the legal framework in 
which biobanks operate (Soini 2016). It defines Valvira (National Supervisory Authority for 
Welfare and Health) to supervise the activities of the Finnish biobanks. In particular, the 
objective of the Biobank Act is to ensure the rights of the donors and to protect their privacy.  
The Biobank Act is currently being renewed in order to better align it with GDPR and the 
national legislation on secondary use of health and wellness data. The new Biobank Act will 
                                               
1 https://www.finlex.fi/fi/laki/ajantasa/1999/19990523#L6P27  (in Finnish) 
2 https://www.finlex.fi/fi/esitykset/he/2018/20180009#idp451117520 (in Finnish) 
3 https://www.finlex.fi/fi/esitykset/he/2017/20170159 (in Finnish) 
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define in more detail the conditions for using data for technical development and innovation 
purposes. 
3.4.5 Genome Act 
The Genome Act is currently in the acceptance process by the Parliament of Finland1. The law 
will regulate the usage and management of genome data. In particular, it will regulate on the 
operation on the National Genome Center to be established under THL as the legal authority. 
The genome centre will promote the use of genetic information in healthcare, research and 
innovation activities in the health sector. The Genome Act is expected to come into force on 
1.1.2019.    
3.5 National strategies  
The value of healthcare data has been recognized in several national strategies.  
The Finnish National eHealth and eSocial Strategy 20202,3 by the Ministry of Social Affairs and 
Health (STM) highlights the potential of data in supporting research, innovation, industrial and 
commercial activities. It brings up the need for legislation to enable secondary use of social 
welfare and healthcare data.  
The Health Sector Growth Strategy4 published by the Ministry of Employment and Economy 
provides recommendations for systematic development of research and innovation activities 
in order to achieve economic growth in the healthcare sector. The strategy report recommends 
seamless joint access to personal health data and patient documents to be enabled for 
research purposes.   
The National Genome Strategy5 recommends the establishment of a national genome centre 
and the development of the related legal framework. The genome center would bring together 
all parties in the field of genomics and it would have the responsibility of developing and 
maintaining a reference database of genomes for the needs of clinical care and research.  
Following the recommendations of the Genome Strategy a specific legislation for governance 
of genome data is currently in preparation6.      
3.6 Isaacus project  
The Isaacus project7 was started by Sitra in 2015 with the objective of setting up an 
organisation to take responsibility of providing access for secondary use of health and wellness 
data. The activity was carried out in parallel with the preparation of the corresponding 
legislation. The Isaacus project included a set of pre-commercial development activities 
chartered to develop components needed by the Service Operator. The components created 
as output from Isaacus were:  
                                               
1 Government bill for Genome law (in Finnish) 
2 https://pdfs.semanticscholar.org/presentation/4c8d/ed88912008cfe7a6bd791e4599a764d29d2a.pdf 
3 http://stm.fi/julkaisu?pubid=URN:ISBN:978-952-00-3548-8 (in Finnish) 
4 Health Sector Growth Strategy  
5 National Genome Strategy 
6  https://stm.fi/en/artikkeli/-/asset_publisher/genomikeskuksen-perustaminen-etenee-tyoryhman-
arviomuistio-lausunnoille 
7 https://www.sitra.fi/artikkelit/isaacus-national-health-data-hub/ 
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 A common metadata model for describing data sets to be searchable via a centralized 
service (activity led by THL)  
 A secure remote environment for data processing (activity led by Statistics Finland) 
 Common processes and tools for biobanks for preparing data sets for research use 
(activity led by BBMRI) 
 A 'one-stop shop' permission service where researchers can apply access to data 
resources  (activity led by National Archives of Finland) 
 Data lakes gathering patient data to be accessible for secondary uses (activities of two 
hospital districts - HUS and VSSHP -  and the City of Kuopio)  
The Isaacus project was running until mid 2018. During the last year Isaacus has been in the 
mode of preparing for the operational phase to be led by THL under the Secondary Use Act. 
The objective is that the components developed by Isaacus could be largely exploited in the 
operational phase of the Service Operator. 
3.7 FinnGen project  
FinnGen is a large precision medicine project launched in Finland during 2017. It is a unique 
study combining genome information with healthcare data. FinnGen differs from many other 
initiatives in collecting a majority of the samples from diseased individuals (with a diagnosed 
disease) using the Finnish hospital biobank network.  This is imperative when studying the 
genetic links to diseases. The project aims to improve human health through genetic research 
and to identify new therapeutic targets and diagnostics for treating a large variety of diseases. 
In the framework of the project, blood samples of 500 000 Finns will be sequenced. The 
samples will be collected by the Finnish biobanks. Currently, already 180 000 samples have 
been collected. The project is lead by the University of Helsinki. It is funded together by 
Business Finland and seven international pharmaceutical companies: Abbvie, AstraZeneca, 
Biogen, Celgene, Genentech (a member of the Roche Group), Merck & Co. and Pfizer. 
During the project, the collected samples and corresponding phenotype data will become 
available for biobank research. Thereby, the project is expected to have a remarkable impact 
in stimulating genome-based research in Finland and internationally. Besides ambitious 
scientific research, the project specifically addresses also needs of businesses and aims at 
involving SME companies in joint add-on projects. 
3.8 MyData  
MyData refers to the paradigm of enabling the individual to have full control over his/her 
personal data. The MyData approach has gained considerable interest during recent years  
and it has been followed by many services, e.g. by exposing API's which allow user data to be 
retrieved in structured form enabling the data to be used in other applications under consent 
by the data subject. The GDPR may reinforce this trend, as it explicitly requires service 
providers to release data to their customers in open reusable formats.   
Despite of the favourable trend, a viable, common MyData architecture has not yet been 
achieved although several related studies and preliminary specifications have been published 
and some early concepts have been presented. Interoperable Personal Health Records 
(PHR's) (Li 2017) can be considered as first MyData implementations. The idea of an 
interoperable PHR is to provide a user-controlled data repository where service providers can 
store personal data in a common format. The Taltioni service was the first implementation of 
this model in Finland, but did not meet its business goals and is now terminated. The Kanta 
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PHR1 being developed is essentially based on the same model, but has better chances to 
succeed as it is a part of the national healthcare infrastructure, potentially enabling it to connect 
with EHR systems. 
The MyData architecture designed and documented in the DHR2 (Digital Health Revolution) 
project is based on a centralized consent management enabling the individual to share his/her 
data between application without implementing any centralized database3.  The IHAN 
(International Human Account Number)4 system proposed by Sitra is another initiative targeted 
to enable the individuals to be in control of their data. In particular IHAN aims at an ecosystem 
with common rules and concepts for data exchange. The MyData model is highly interesting 
from the PreMed project perspective as it would enable a convenient way to obtain the data 
subject's consent for using the data in the cases where direct secondary use of personal data 
is not permitted.  
3.9 Finnish health and social services reform 
A major health and social services reform is being implemented in Finland5. A key objective of 
the reform is to assign the responsibility for providing public healthcare and social services to 
18 autonomous regions. These regions are considerably larger than municipalities, which 
currently are responsible for arranging the services. An important long-term objective is to 
achieve considerable savings through new operating models and efficient processes.  
The reform will be accompanied by considerable investments in ICT systems. In addition to 
the basic functionalities, such as care documentation in EHR systems, there will be increased 
need for monitoring the quality and efficiency of service processes. This need is reinforced due 
to the fact that the healthcare customer will be given more freedom in selecting the healthcare 
provider. Both public and private social and health services centres will be available to choose 
from.  In order to use the freedom to choose, the customer needs clearly expressed information 
on the quality of the available services. Graphical summary information can be created by 
software applications which can access a wide range of up-to-date data.  Consequently, the 
health and social services reform is likely to increase the need for secondary use of data. 
3.10 Data users  
Data users are entities which directly or indirectly benefit from the secondary use of data. Direct 
data users access original individual level data. Indirect data users refer to entities, which 
cannot or do not want to access individual level data directly, but benefit from data analytics 
results and aggregated summary data provided for them.         
Universities and research institutes have a long tradition of secondary use of data. The use of 
registry data is a cost-efficient alternative compared to experimental studies and enables very 
large populations to be studied. Usage of registry data for scientific research is clearly covered 
and supported by the corresponding laws, including the GDPR.  
Public and private health service providers are increasingly showing interest towards 
secondary use of patient data - not only for traditional academic research, but increasingly also 
for monitoring and improving healthcare processes and quality. Analysis of patient data would 
also be useful when selecting patients for targeted preventive interventions. Moreover, it 
enables data-driven clinical decision support systems (CDSS), where patient's health 
parameters are compared to similar reference patients. Development of such systems requires 
                                               
1 https://www.kanta.fi/en/web/guest/professionals/kanta-phr 
2 http://www.digitalhealthrevolution.fi/ 
3 http://hiit.github.io/mydata-stack/ 
4 https://www.sitra.fi/en/topics/human-driven-data-economy/#what-is-it-about 
5 http://alueuudistus.fi/en/social-welfare-and-health-care-reform/about-the-reform 
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secondary use of data even if the actual CDSS system would be used only in the context of 
patient care and thus categorized as primary use of data.    
Public authorities are an important data user group. It is commonly accepted that public 
investments and political decisions should be based on knowledge and evidence, which in 
most cases requires real-world data analytics. National statistical registers have been available 
for such use for long, but there is a need to access more detailed data and data in a wider 
scope. There is also a need for easy-to-use and understandable user interfaces providing 
actionable information for the users, as is the case in the MIDAS project (Meaningful 
Integration of Data, Analytics and Services)1.      
Citizens benefit from secondary data indirectly in the form of services provided for them. 
Healthcare statistics are publicly available and can be accessed by individual citizens. More 
typically, citizens consume such information in the form of newspaper articles and other media 
content prepared by journalists and bloggers.    
Several types of companies are potential direct or indirect data users. We have identified the 
following groups: 
 Pharma and diagnostics  
 Research and expert services 
 Bioinformatics software and services 
 Sequencing, genotyping and diagnostics services 
 Genetic test interpretation and counselling services 
 Medical device manufacturers 
 Healthcare information system and application providers 
 Healthcare services 
 Insurance services  
 Food and nutrition 
 
Pharma and diagnostics companies have a long tradition of using patient data under patient 
consent in various phases of drug development and in Real-World Evidence (RWE) studies. 
Most typically pharma companies subcontract these studies to be carried out by external 
research and expert services companies such as contract research organisations (CRO's).   
Bioinformatics software and services providers are typically SME's, which have developed 
software for genome or other omics data analytics and offer related services for their 
customers, such as pharma companies or research service providers.       
Sequencing genotyping and diagnostics providers are companies with laboratory facilities 
and capability to provide genetic diagnostic tests and genome sequencing services.  
Genetic test interpretation and counselling services refer to various types of services 
supporting the exploitation of the raw genome data in healthcare e.g. as in pharmacogenomics 
(business-to-business, B2B) or independently by the consumer to support preventive self-care 
(business-to-consumer, B2C).   
Medical device manufacturers are potential users of health data to support their R&D 
activities. In a typical case, the device manufacturer is interested in collecting data from the 
use of their existing products. External data resources could potentially be used to support the 
R&D towards new products.    
                                               
1 http://www.midasproject.eu/  
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Healthcare information systems and applications  are increasingly including advanced 
decision support features providing guidance to clinicians and patients. Developing, tuning and 
further development of such features requires individual level health data to be available.    
Healthcare services companies - similarly to public healthcare providers - need data for 
monitoring and improving healthcare processes and quality.  
Insurance services  have strong interest in health data. Ethical issues and the fear of loosing 
customers prevent insurance companies from using individual level health data. However, 
insurance companies can indirectly benefit from aggregated health data, e.g. in getting a better 
understanding of the mechanisms leading to disablement, and of the related preventive 
interventions.     
Food and nutrition companies need data on citizen's lifestyles and health e.g. in the 
development of products for personalized nutrition. Besides targeted questionnaires, the public 
data resources collected e.g. by THL are potentially attractive for the R&D activities.      
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4 Review of international activities  
In this Chapter, we provide a global review on national initiatives and organisations in the field 
of precision medicine (PM). As precision medicine ecosystems largely rely on exploitation of 
genomic and health data, we introduce internationally available genomics and health data 
sources, centralized data storages, data services, and related resources. We also provide a 
brief outlook on the overall market size.   
As the constantly declining costs of genome sequencing make widespread application of 
genetics increasingly plausible1, its business potential and promises of better healthcare 
become more apparent. Recently governments world-wide have implemented major initiatives 
to facilitate national growth of genomic research, markets, and clinical implementation of PM 
innovations. Alongside governments, research institutes, industry and collaborative 
organizations intend to share, harmonize and consolidate genomics and health data by 
establishing biobanks and databanks, data infrastructures, data standards and computing 
services. It is becoming increasingly evident that efforts towards precision medicine marks a 
key global development in several omics, data and healthcare related sectors.  
4.1 Data collection 
In order to map the precision medicine landscape, we made a review to locate recent global 
initiatives, major national and international organisations, and commercial companies that 
promote collaboration and data sharing in the precision medicine domain. We aim to 
demonstrate prominent, up-to-date and recent precision medicine efforts in Europe and 
globally. We have included a variety of efforts such as research projects, collaborator 
organisations, investments to build data infrastructures and databases, and strategic plans to 
support genomic science, innovation, and economy. Precision medicine related projects were 
searched by combining keywords such as ‘precision’, ‘personalized’, ‘genomic’, ‘initiative’, 
‘medicine’ and names of countries or continents. The initial findings were used to locate 
references to major organisations not found in the primary searches. We narrowed the findings 
by including only up-to-date organisations, and excluded initiatives with outdated online 
information. To locate commercial companies, we used the member-lists of two major 
precision medicine associations, one in Europe and one in the USA.  
4.2 Market outlook 
There is a variety of commercial organisations providing services and products to the precision 
medicine markets. For example, current members of the Personalized Medicine Coalition and 
The European Personalised Medicine Association, include a number of commercial clinical 
laboratory testing services, diagnostic companies, biotechnology and pharmaceutical 
companies, healthcare insurance companies, IT and informatics companies, service providers, 
research tool companies and venture capital investors2.  
The commercial services within data-driven precision medicine range from analysing data, to 
generating data platforms and cloud services, and to utilizing the data in services targeted for 
the individual consumer. DNA sequencing is often outsourced to specialized companies, as is 
in the case of Genomics England, which uses Illumina to sequence the collected DNA samples 
in the 100 000 genomes project. Large-scale computing services provide platform services, as 
in the case of Amazon Web Services that hosts a precision medicine platform for the American 
Heart Association. Data analysis and informatics companies such as SevenBridges or Syapse 
provide not only platform services, but also detailed analytics and infrastructure services to 
businesses. Potentially disruptive companies have emerged and might emerge in areas 
targeting individual consumers, as in the case of 23andMe or FitnessGenes that base their 
                                               
1 https://www.genome.gov/27565109/the-cost-of-sequencing-a-human-genome/ 
2 http://www.personalizedmedicinecoalition.org/Members/Current_Members 
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product on interpreting individual DNA samples to provide information on lifestyle and health 
risks.  
Market research organisations estimate a significant growth in overall precision medicine 
markets for the coming years. Frost and Sullivan estimate that global precision medicine 
markets will grow from 38 billion dollars in 2015 to 134 billion dollars in 2025 (Frost&Sullivan 
2017a), and that oncology related markets will cover 40-50% of the market (Frost&Sullivan 
2017b). Roughly similar estimates are made by other market research companies, estimating 
that the compound annual growth rate of global precision medicine markets will be between 
9,7 % to 14 % in the coming seven years1.  
4.3 Current precision medicine initiatives 
This section presents the aims and goals, estimated funding, and sequencing targets of a 
number of key initiatives, strategies and research projects in the field of precision medicine. 
We list national and academic projects currently actual in several countries throughout the 
world. We found that the surveyed initiatives have roughly similar overall aims and goals, but 
the sequencing targets and economic investments vary significantly. A list of the initiatives  and 
collaborative organisations are found in Appendices 1 and 2 respectively.  
Precision or genomic medicine initiatives, research programs and strategies are currently in 
progress on a large scale in several countries. In the last year alone, new initiatives in Europe 
have been launched in Denmark, Finland, Sweden, and Switzerland. Since 2015, China, 
Japan, South Korea, New Zealand and the US have initiated similar efforts. Earlier started 
projects include the international H3Africa project, which launched in 2010, and the Estonian 
Biobank which has been collecting samples for almost 20 years.   
Funding of national projects vary from initial investments of a few millions to more ambitious 
and long-term investments counted in hundreds of millions. For example, Denmark has made 
an initial investment of 13 M€ for their national PM strategy during 2017-2022, and Switzerland 
will allocate around 60 M€ for PM development projects during 2017-2020 through their 
Personalized Health Network. In comparison, South Korea invests 48 M€ in a single cohort 
study aiming to sequence 10 000 cancer patients. More ambitious investments ranging from 
250 to 670 million euros have been made in US, France and UK to support national PM 
initiatives. These are large scale sequencing projects that aim to sequence from 100 000 to 1 
million individuals. China is in unique in comparison, as the government aims to support 
precision medicine projects nationally with about 8000 M€ in order to sequence up to 100 
million genomes in the population in the coming 15 years.  
The data collection methods and amount of genome sequencing plans in research projects 
and population sequencing initiatives vary in a similar manner. Genomic Medicine Sweden 
aims to sequence 25 000 genomes annually in the future, while the French aim at 235 000 
annual genomes. The FinnGen research project uses samples collected by Finnish biobanks 
and aims by 2023 at a total of 500 000 sequenced genomes combined with phenotype data 
available from national registries. Genomics England plan to sequence 100 000 genomes 
related to 75 000 individuals, while also collecting lifestyle and health data by using electronic 
health records. While the emphasis in data collection is often in understanding the genomic 
variation and utilization of genomic knowledge in healthcare, national strategies also highlight 
the use of various data sources, big data and data sharing as a means to advancing the main 
goals of precision and preventive healthcare. Examples of research projects using various data 
                                               
1 Frost and Sullivan (2017a) estimate a CAGR of 13,3 % during 2015 to 2025.  
Mordor Intelligence estimate that the precision medicine markets will grow at a CAGR of 9,7 % during 
2018-2023. https://www.marketresearchfuture.com/reports/precision-medicine-market-925 
Market Research Future estimate a CAGR of 12,48 % between 2015-2022 
https://www.mordorintelligence.com/industry-reports/precision-medicine-market 
Persistence Market Research predict a CAGR of 14 % from 2016 to 2024 
https://www.persistencemarketresearch.com/market-research/precision-medicine-market.asp 
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is FinnGen, Estonian Genome Project or Genomics England, all of which will produce 
extensive and longitudinal databases that combine genomic, lifestyle and health data.  
Despite of organisational differences between the type of the initiatives (e.g. national strategy, 
biobank, research project), the objectives and aims of each initiative are roughly similar. Many 
of the initiatives aim for scientific advancement and practical implementation of personalized 
medicine through supporting national research infrastructures, collaborations, data sharing 
and data harmonization nationally and globally, and kick-starting precision medicine 
innovations and markets. These goals are similar to what Dubow and Marjanovic (2016) found 
in their study comparing 30 national sequencing initiatives.  
The recent years have also seen global collaborations and advocacy groups emerge 
(Appendix 2). For example, the Global Genomic Medicine Collaborative and the International 
Consortium for Personalised Medicine (ICPerMed) were established in 2016. Older 
collaborations around precision medicine include the Personalized Medicine Coalition (2015) 
and the European Personalised Medicine Association (2009). These organisations are formed 
to create and support networks and collaborations, raise awareness and highlight benefits of 
PM in order to accelerate its adoption and development. A more data driven approach is 
offered by the Global Alliance for Genomics and Health that promotes responsible genomics 
data sharing by developing technical standards and framing related policies. They offer free 
toolkits for sharing genomics data according to ethical and regulatory frameworks, data 
security and genomic data analysis. 
4.4 Overview of key data sources, storages and centralized services 
In this section we introduce widely available genomic data sources, data tools, structures and 
services. We surveyed websites and documents from precision medicine related organisations 
to map resources available for commercial and other non-academic actors in precision 
medicine (see Table 1 and Appendices 3 and 4). We also studied how organisations explicitly 
state to support SMEs, the industry or otherwise commercial use.  
Table 1 includes a list of organisations that provide different kinds of health or genomics data 
related services. We found 3 types of key resources. These include data access and 
restrictions by which access is controlled; computing and analysis resources such as tools and 
testing environments; and other resources, such as education, industry support strategies 
including specialized SME programs, or forums to facilitate commercial collaboration.  
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Table 1. Available data sources, tools, and other resources  
Project Data access Tools Other resources 
open restric
ted 
access 
fee 
links 
to 
data 
data 
analysis 
tools 
testing 
environ-
ments 
industry 
support 
program 
training or 
education 
collabo-
ration 
resources 
The Estonian 
Genome Center 
 X X  X     
UK Biobank  X X       
Canadian Open 
Genetics 
Repository 
(COGR) 
X         
Hartwig medical 
foundation (NL) 
 X X       
European 
Genome 
Phenome 
Archive (EGA) 
 X        
International 
Cancer Genome 
Consortium 
(ICGC)  
X X   X X    
The National 
cancer Institute 
(NCI), Genomic 
Data Commons 
(GDC) (USA) 
X X  X X X    
European 
Bioinformatics 
Institute (EMBL-
EBI) 
X X  X X  X X X 
PrecisionFDA 
(USA) 
 X   X X   X 
AHA Precision 
Medicine 
Platform (USA) 
 X X  X X   X 
The National 
Genomics 
Infrastructure 
(NGI) (SWE) 
   X X    X 
ELIXIR (Europe)    X X  X X X 
The 100 000 
Genomes 
Project 
(Genomics 
England) 
 X     X  X 
FinnGen (FIN)  X        
LifeGene (SWE)  X X       
The Personal 
Genome Project 
(International) 
   X     X 
Global Alliance 
for Genomics 
and Health 
(GA4GH) 
    X    X 
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While biobanks (Appendix 4) and some research projects are organisations that mainly provide 
access to data or samples, other platform-type organisations provide wider, often free-of-
charge services, including computational infrastructures and tools for analysing, testing, 
sharing, submitting or downloading data (Appendix 3). 
4.4.1 Data access policies  
Table 1 depicts organisations that offer organisations and researchers access to a variety of 
data sources (see Appendices 3 and 4 for detailed information). Half of the organisations 
presented host datasets containing health, lifestyle and genetic data. Four organisations focus 
solely on molecular level biological or cancer-related data, and three of the surveyed 
organisations are collaborative data infrastructures that function as catalogues to external data 
sources without providing their own data.  
There are different ways to gain access to the data. Data access restrictions depend on access 
policies, the type service provided, or anonymity of the data. Open access datasets means the 
data is freely available for download without restrictions. There are various approaches for 
providing or supporting open data access. For example, the Canadian Open Genetics 
Repository (COGR) pools data from medical diagnostics laboratories in Canada to create a 
publicly available, open access repository of human gene DNA variants. A similar, but more 
international effort is the Personal Genome Project, which is a coalition that supports publicly 
shared genome, health and trait data1. Its participants are encouraged to create voluntary, 
non-anonymous (i.e. researchers do not promise anonymity for participants), open-access 
data. The data is freely available on the participant’s websites and proves that even non-
anonymous health and genome data is publicly available.  
With the exception of the Personal Genome Project, only anonymous, molecular level data 
was available for open access in our review. Organisations maintaining open access data such 
as The Genomic Data Commons (GDC) and the International Cancer Genome Consortium 
(ICGC), hold cancer specific data on genomic, epigenetic and transcriptomic levels. The 
European Bioinformatics Institute (EMBL-EBI) provides a variety of biological data sources, 
including DNA and RNA, gene expressions, proteins structures, systems, chemical biology 
and related ontologies. In contrast, organisations that hold combined clinical, lifestyle and 
‘omics’ datasets, such as the UK Biobank, Estonian Genome Center and LifeGene research 
project, restrict access to data.  
Restricted data access refers to datasets that are controlled by a data access committee 
(DAC), that have an access fee, or otherwise set conditions for accessing data. The DAC 
usually requires a research proposal or other documents to legitimize the use of the data. 
Restricted access is common for organisations that sustain datasets that vary in the level of 
anonymity, and it is common that access to less anonymous datasets is limited. For example, 
the Genomic Data Commons (GDC) makes non-identifiable high-level genomic data publicly 
available through a data portal, but access to individually identifiable data is granted by a DAC2. 
The European Bioinformatics Institute (EMBL-EBI) and the International Cancer Genome 
Consortium (ICGC) follow similar practices.  
As biobank research typically involves rich individual-level data sets and samples it is clear 
that diligent data access management need to be applied. The UK Biobank ensures 
appropriate use of all their data by requiring registration and application through an access 
management system3. From the data user perspective it is important that clear guidance and 
data access process is available. Appendix 4 indicates some user guidance approaches taken 
by biobanks and other data providers. It can be seen that guidance and prices are largely 
published and some biobanks also have forms for data applications and data availability 
                                               
1 https://www.personalgenomes.org/ 
2 https://gdc.cancer.gov/access-data/data-access-processes-and-tools 
3 http://www.ukbiobank.ac.uk/register-apply/  
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requests. It is remarkable that most collections are globally available, although some of which 
require collaboration with a local partner. Suitable data and sample contents can be exploited 
worldwide, which considerably enlarges the likelihood for data users to find resources 
matching their needs.           
Access fees. It is common for biobanks to charge a fee to cover the service costs for providing 
access to data. Other organisations such as the AHA state that they provide open access to 
cardiovascular datasets, but they take a fee for the cloud computing capabilities used1 while 
analysing data on the platform. Some organisations have different fees for academic research 
organisations and commercial use of the data. For example the Hartwig Medical Foundation 
takes a fee when accessing data for commercial purposes2. 
Apart from research proposals and access fees, some biobanks and research projects have 
conditional data access. For example, LifeGene (Sweden), the Danish National Biobank and 
Hunt (Norway) require applying organisations to be associated with national research institutes 
or universities. Some organisations directly deny data access from most external parties by 
involving exclusively their core research partners or data service providers. The 100 000 
Genomes Project allows full data access for partner researchers and institutions, while offering 
a limited data access to commercial parties through a ‘discovery forum’3. 
Access to external data. The National Genomics Infrastructure (NGI) in Sweden and Elixir 
are examples of data infrastructures that bring together a variety of resources in order to 
coordinate and facilitate genomics research, provide access to training, tools and external data 
resources. These organisations provide lists of datasets to be accessed via external partners. 
The Personal Genome Project is an international collaborative platform for researchers sharing 
publicly accessible genomics, trait and health data and data is accessible via involved 
institutions.  
4.4.2 Available data analysis tools and computing resources 
Many organisations provide computational infrastructures for analysing, testing, sharing, 
submitting and downloading data. While the platform-type organisations might function as 
valuable assets for research oriented SME's, their primary function is to support the research 
community and often basic research. The tools and testing platforms offered are mostly free 
of charge resources set up in order to support analysing and consolidating the vast amount of 
genetic and health data.  
Several of the surveyed organisations provide access to various resources created in order to 
analyse, test and develop data analysis. There is a plethora of freely available tools for different 
analysis, visualisation and testing functions. For example, The European Bio Informatics 
Institute (EMBL-EBI) lists up to one hundred different tools to help analyse data from the 
molecular data resources4, and Elixir provides a registry for browsing and searching for 
available software and data resources5.   
Providing software tools can be used as a means to standardize processes of analysing and 
reporting data. The Global Alliance For Genomics And Health (GA4GH) shares toolkits in order 
to push the organisation’s mission for setting standards, enable responsible sharing of 
genomic data and frame policies accordingly. Thus they list tools that enable sharing, storing 
and retrieval of data, but also tools for data security and even ethical toolkits. The Automatable 
Discovery and Access Matrix for example, is a tool that standardizes the way consent and 
                                               
1 https://precision.heart.org/tos 
2 https://www.hartwigmedicalfoundation.nl/wp-content/uploads/2017/03/Rules-of-Procedure_ENG.pdf  
3 https://www.genomicsengland.co.uk/working-with-industry/  
4 https://www.ebi.ac.uk/services/all   
5 https://www.elixir-europe.org/platforms/tools  
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conditions of data use is represented, enabling easier digital communication, automation and 
sharing1. 
A few organisations also provide sandbox-type testing and developing platforms. The 
International Cancer Genome Consortium (ICGC) has tools for enrichment analysis, cohort 
comparison and visualising genetic alterations2. They also provide a Jupyter sandbox tool for 
secure experimenting and exploring. The same tool is used by the AHA Precision Medicine 
Platform. A similar type of testing environment is available in the precisionFDA platform that 
has sandbox features for experimenting, data sharing and for creating apps3.   
4.4.3 Services for companies 
While all of the surveyed organizations aim, in one way or another, to support the research 
community and genomics research, some organizations also explicitly aim to support 
commercial use of their data and tools. For example, Genomics England facilitates 
collaboration and engagement between industry, academia, NHS and others through their 
‘Discovery Forum’4. Elixir provides similar resources with their ‘industry programme’ set up to 
support industry, stimulate innovation, and reduce barriers between company research 
partnerships5. Elixir also has an “Innovation and SME programme“ that hosts events for SME's 
in national nodes across Europe.  
The European Bioinformatics Institute facilitates an Industry Programme aimed mostly at 
maintaining contact with major pharmaceutical companies using EMBL-EBI in their R&D6. The 
organization reports that they support SME's through free data access, tools and infrastructure. 
They also organize networking events in collaboration with other organizations such as Elixir 
SME forum. Both Elixir and EMBL-EBI also maintain training and education programs 
accessible to both academic and private enterprise researchers.  
4.5 Implications for Finnish companies 
Innovations in the ‘omics’ sector, pharmaceutical R&D, clinical care, IT and big data, and 
personal health services, build largely on the capacity to form meaningful outputs and uses 
from heterogeneous data sources. Thus, several countries invest large sums to sequence 
populations in order to create data, to form national data infrastructures facilitating data use, 
to support research utilizing the data and to develop innovative products and services. The 
question for policy makers, research organisations and companies remain how to collect 
standardized and meaningful data in an ethically sound way, and how to efficiently exploit the 
data in science and business, thereby unlocking the potentials of precision medicine.  
As shown in Section 4.4, national and international data resources are widely available. Some 
of these organisations host significant data sources including ‘omics’ data, clinical health data, 
and lifestyle data. Typically, anonymous genomic sequence data or aggregate health data is 
openly available. Such data may be highly valuable to SME's especially in the  bioinformatics 
domain.     
Non-anonymised data and data combining various genomics, health and lifestyle information 
is mostly available only for scientific research studies. Such data sets - combining genotype 
and phenotype information - are available mainly through biobanks and university hospitals. 
Access is restricted to scientific research studies and in some cases limited to be used in co-
operation with local research partners. Still, the precision medicine field in Finland can benefit 
from the fact that research organisations can access high-quality international data resources 
                                               
1 https://www.ga4gh.org/ga4ghtoolkit/regulatoryandethics/  
2 https://dcc.icgc.org/analysis  
3 https://precision.fda.gov/docs/creating_apps  
4 https://www.genomicsengland.co.uk/working-with-industry/  
5 https://www.elixir-europe.org/industry  
6 https://www.ebi.ac.uk/industry  
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in addition to national data sources. Apart from universities and research institutes, benefits 
can be foreseen to come through internationally oriented companies, which can make quality 
research complying with scientific standards and which can use this knowledge in providing 
services for other companies. Networks and ecosystems need to be formed to connect 
research providing companies to the heterogeneous group of companies with research 
questions and information needs.  
As revealed by this review, various organisations provide data analysis tools, or help 
commercial entities by providing education or forming collaborations. Such resources and 
infrastructures can be very useful for Finnish SMEs. For these companies the biggest benefit 
appear to come from platform type organisations offering data, analysis tools, testing 
environments and collaborative structures. 
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5 Interviews 
In order to get an understanding of the current precision medicine landscape in Finland, 
interviews where performed with various stakeholders during the first phase of PreMed in 
2017-2018. The focus was to understand the organisations in general, their value chain(s) and, 
the meaning of health data for them. We also wanted to know about the stakeholders' 
expectations on the FinnGen project and its contribution to the Finnish precision medicine 
ecosystem. The results of the interviews collect general views of the players as well as their 
wishes and doubts.  
5.1  Methods  
In order to get key persons from the organizations for the interviews a flexible approach was 
taken. Most interviews where performed face-to-face at their premises, but some by Skype or 
by phone in case of scheduling problems. The duration of the interview was typically 1-2 hours. 
The interview was recorded in some cases, after given oral permission of the interviewed 
person. The interviewed experts are listed in Appendix 5.    
A set of questions was used as the basis for the interviews (Appendix 6). However, due to the 
heterogeneity of the target group, all listed questions were not relevant for all interviews. 
Therefore, freedom was given to follow the flow of the interview and take up issues during the 
discussions. In all cases, the direct comments have been kept anonymous in reporting the 
results.  
5.2  Interviewed organisations 
It has been estimated that the Finnish health technology sector contains over 400 companies, 
most of which are fairly small (over half of them have less than 10 employees)1. Only some of 
these where selected for interviews based on their relevance with respect to exploitation health 
data and genome technology. Other stakeholders interviewed include e.g. biobanks, hospitals 
(private and public), pharma companies and various service providers. In addition to the formal 
interviews we also contacted additional pharma companies for informal discussion, especially 
to get a wider perspective for planning the next project phases.     
As listed in Table 2, altogether 32 interviews and 6 informal discussions were carried out. Table 
2 also indicates four earlier interviews (carried out Autumn 2016), which we exploited in the 
study. The used classification of organisations is approximate, as some companies may 
belong to several classes.   
                                               
1 Suomen terveysteknologia-alan nykytila ja haasteet (340/207, Tekes) 
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Table 2. Organisations involved in interviews and informal discussions 
Organisation category Organisations  
Biobank Auria biobank, FINBB, Blood Service 
Biobank, Helsinki Biobank** 
University, hospital district, research 
institute 
VSSHP, University of Eastern Finland , 
THL, Sitra 
Research and expert services Medaffcon, Medengine, CrownCRO* 
Bioinformatics software and services BC Platforms, Euformatics, Genevia, 
Medisapiens 
Sequencing genotyping and 
diagnostics services 
Blueprint Genetics*, Zora Biosciences* 
Genetic test interpretation and 
counselling services 
Abomics, Diagfactor 
Medical devices manufacturer GE Healthcare, Modulight 
Pharma and diagnostics  Orion, Abbvie, Pfizer, Novartis**, Roche**, 
Bayer**, Boehringer Ingelheim**, Janssen** 
Healthcare information systems and 
applications 
Duodecim, BCB Medical, Kaiku Health, 
Odum, Quattrofolia, Mediconsult* 
Healthcare services Mehiläinen, Terveystalo, Docrates, Aava  
Insurance services  Lähitapiola 
Food and nutrition Fazer, Raisio 
 
* Interview carried out before PreMed project context in Autumn 2016.  
** Informal discussion  
    
5.3 Observations from interviews and discussions 
In general, the interviews reflected the growing need of companies to exploit health-related 
data. The FinnGen project was considered as a great opportunity to increase the exploitation 
of genotype combined with phenotype data and to increase the visibility of Finland in this field. 
The dramatic drop of sequencing cost was noted in several interviews to be an important driver 
for large-scale exploitation of genome technologies.  A common hope was that - besides 
benefits for academic research - the FinnGen project would also bring benefits and 
opportunities for companies.  
Many of the interviewed companies highlighted the need for various types of health data, 
including personal health monitoring and life style data. Genome data was considered only as 
one data type among the others, although its growing importance was recognized. In this 
respect, the opportunity to access data through a single service point  (Service Operator) as 
defined in the Secondary Use Act was warmly welcomed.  
The legislation, in particular the Secondary Use Act and the Biobank Act, where considered to 
give competitive advantage to Finland along with the Finnish social security number, the 
genetically unique population and high-quality health data resources.                   
The current status and needs concerning data and genome technology exploitation for each 
company category is summarized in the following subsections. Related bottlenecks and 
challenges are addressed in Section 5.4. The observations are based on the interviews and 
informal discussions with stakeholders listed in Table 2.  
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5.3.1 Pharma and diagnostics companies   
Pharma and diagnostics companies have a long tradition of using patient data in various 
phases of drug development and in Real-World Evidence (RWE) studies. Data analytics is 
carried out in-house and in the context of extensive academic collaborations. RWE studies are 
complementary to clinical trials carried out under informed consent of the study subject. They 
are highly important to pharma companies for example in the process of getting drug 
reimbursement decisions from the authorities. RWE studies are also important in providing 
information on the use of the drug in the context of adaptive pathways1. Adaptive pathways 
refer to bringing drugs faster to markets by reducing the need for clinical trials before marketing 
authorization. Adaptive pathways are applicable in the context of life-threatening diseases 
where there are no existing treatment options.  
Access to health data registries is not only important for RWE studies, but also for patient 
stratification in preparation for clinical trials. Additionally, omics data has an increasing 
potential in the early phase of drug development as it enables an understanding of the 
underlying biological mechanisms and possible adverse effects as well as in finding new 
biomarkers for medical diagnostics.  
Multi-national pharma companies are continuously evaluating candidate countries for drug 
development, clinical trials and RWE studies. Availability of high-quality data efficiently and 
within predictable time schedules is an important selection criteria. The interviewees felt that 
Finland is in a good position thanks to statistical registers systematically collected over long 
time periods, but the processes for accessing the data are too slow. Consequently, pharma 
companies have high expectations on the Service Operator and biobanks in being able to 
develop systematic and efficient processes for data access. It was also brought up that Finland 
is a small country and should invest in collaborative analytics in international context to 
maximize benefit of its data resources to the scientific and medical communities.        
5.3.2 Research and expert services  
Research and expert service companies are carrying out clinical trials and RWE studies under 
contract with pharma companies. They are in a key role in accessing the data sets for the 
studies, and therefore the needs to improve the data access processes were pronounced. In 
the interviews, also the need for clear legislation and rules concerning data access was raised. 
Besides the pharma sector, also healthcare organisations are an important customer group 
and there are signs of other emerging customer groups, such as medical device 
manufacturers.  
5.3.3 Medical device manufacturers  
There is a clear trend of increasing intelligence to medical devices and, in particular, collecting 
data from networked devices (Internet of Things, IoT) to be jointly analysed. This trend applies 
especially to monitoring systems at intensive care units (ICU) and wards in hospitals. The 
objective of patient data analysis is to obtain a holistic, real-time view of the patient for the 
clinicians and initiate alarms as needed. The combination of various types of data enables also 
predictive models to be created. Development and tuning of such models requires availability 
of monitoring data sets. Getting permissions for data access separately from different hospitals 
is laborious. Consequently, there is a high demand for a centralized services covering not only 
statistical registers, but also detailed patient data in hospital data lakes.     
5.3.4 Bioinformatics software and services  
Bioinformatics software and services companies carry out data analytics and interpretation on 
individual-level data. The data is typically provided by the customer in the context of a work 
                                               
1 EMA Guidance  
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assignment. Consequently, challenges of accessing data are not pronounced in the interviews. 
The data analytics projects typically exploit in-house software, which is also available to be 
purchased by the client. A new opportunity is seen in embedding data analytics software 
modules in medical devices. The interviewed companies are globally oriented and already 
have a remarkable share of their business with international customers.        
5.3.5 Sequencing, genotyping and diagnostics providers  
Sequencing, genotyping and diagnostics providers are companies with laboratory facilities. 
The companies range from SME's with focused test product offerings to large international 
companies with wide spectrum of laboratory services. In general, these companies gain from 
increased demand for omics studies in the context of biobank research and the use of 
biomarker-based tests in healthcare. Access to data is not of high priority for companies 
focusing in laboratory services, but some of the companies in this group have also activities in 
the data analytics domain.  
5.3.6 Genetic test interpretation and counselling services 
These SME companies base their business on supporting the use of genome data in 
healthcare or by individuals. A typical example is pharmacogenomics (Ji 2016). Metabolism of 
certain drugs is dependent on known gene variants, which has to be taken into account when 
selecting the appropriate drug and dose. This motivates the healthcare service provider to 
order the respective gene test and interpretation service. Interpretation and counselling 
services are also provided directly to consumers. In this case, the gene test typically addresses 
health risks or hereditary diseases. In offering these services the SME's do not directly need 
data resources. However, genome sequencing of large populations may have a  favourable 
effect as it potentially increases demand for interpretation and counselling services.  On the 
other hand,  data would be needed for RWE studies to reveal evidence on the accuracy and 
impact of the tests.  
5.3.7 Healthcare service providers 
Healthcare service providers have strong interest towards secondary use of health data from 
many perspectives. At university hospitals and other clinical service providers, there are 
healthcare professionals carrying out clinical or registry-based research. Hospital data lakes 
and biobanks are quickly emerging and are already in active use. The Service Operator and 
joint biobank services are expected to provide further benefits in accessing data and sample 
resources of different controllers and in providing the necessary processes for finding and 
getting permissions to access the resources.       
On the other hand, access to health data is needed for monitoring and analysis of healthcare 
quality and processes. Another example, brought up in the interviews was monitoring of 
wellbeing of employees as part of an occupational health service. Such applications are based 
on the data controlled by one organisation and, in these cases the Service Operator is not 
expected to bring additional value. The usage of genetic testing is still relatively modest in the 
day-to-day healthcare practices. According to the interviews, more evidence on the benefits 
are needed and the guidance should be incorporated in the care guidelines.       
5.3.8 Healthcare information systems and applications 
In this category, there are large and small companies providing information systems and 
applications to healthcare professionals and citizens. Information systems and applications are 
not anymore only for data management and viewing. Instead, there is a need for converting 
the data into useful information through advanced decision support, reporting and  visualisation 
functionalities. The development of such advanced functionalities relies heavily on access to 
data. On the other hand this category of companies benefit from the growing demand for quality 
registers and biobank information systems powered by secondary use of data.    
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5.3.9 Insurance services 
Insurance services are interested in using health related data e.g. in designing new products 
motivating individuals for health maintenance. Population-level information e.g. concerning 
geographical differences and dependency between lifestyles and diseases are highly 
interesting and could be used in new insurance products and in insurance pricing strategies. 
Insurance companies are extremely careful in maintaining their reputation towards customers. 
Consequently, there seems to be no plans for secondary use of individual-level health data 
directly.  
5.3.10 Food industry  
Companies in food and nutrition industry are focusing R&D efforts towards new products with 
positive health effects. There is an increasing interest towards working together with employers 
in order to manage health risks of employees. Such activities include targeted interventions for 
risk groups and combining the elements of nutrition and physical exercise. The understanding 
of personalized effects of food is of high importance and has motivated several research 
activities. The future is foreseen where optimum diet for an individual can be constructed by 
using individual-level data, including genome and microbiome data. Especially, the effect of 
microbiome on health and the possibility of modifying the microbiome with the help of food are 
currently under extensive research.     
Access to individual-level data storages is an important opportunity to increase the 
understanding of individuals' differences in response to food. A big challenge for research is 
how to reliably collect information about the human behaviour - e.g. intake of food.    
5.4 Bottlenecks and challenges 
As indicated in Section 5.3 there are high expectations towards data-driven precision medicine 
and the recent efforts in improving access to health data are widely appreciated. However, the 
interviews revealed also a number of bottlenecks and challenges. The main issues have been 
collected in Table 3 divided into groups: healthcare, pharma, SME companies, data access 
and public policy.  
Healthcare and pharma development are the main drivers for data exploitation. Many SME's 
seek co-operation with larger organisations, but face difficulties.  For example, in healthcare, 
the use of genome and other omics tests has not increased as fast as hoped, and consequently 
the demand for such services stays low. The companies also feel that access to Finnish 
hospital processes for real life testing of new inventions or for clinical studies is not always 
easy. In some cases, testing abroad is easier and faster, and innovations are adopted faster 
outside Finland. This has led to companies establishing units abroad and, consequently 
economic benefits both for our domestic healthcare as well as our export business have been 
lost or delayed. Furthermore, many SME's feel that FinnGen does not offer concrete options 
for collaboration for them.  
In pharma sector, the main bottleneck is that drug reimbursement decisions and regulatory 
approvals take too much time, which causes the drug development costs to increase. Also 
access to data should be faster and better organized. Although the Service Operator, joint 
biobank services (FINBB) and the Genome Center are considered as positive initiatives, many 
of the interviewees were worried about the slow progress. Similar concerns related to 
coordinating biobank activities are also faced in other countries (Chalmers 2016).    
Concerning public policies, it was pointed out that financing of R&D has been falling during 
several years, which implies that Finland's advantage is quickly reducing. Lack of coordination, 
standard interfaces and competences were other issues slowing down the development.      
 
              31 (75) 
 
 
 
The collaboration of the Finnish Biobanks was regarded crucial by many of the interviewed 
stakeholders. The newly established  FINBB was considered to be important in this respect, 
but its role was considered still somewhat unclear with respect to the individual biobanks. 
The pricing of data and samples seems to be a challenge in many respects. Public biobanks 
benefit from public resources in collecting data and samples. Therefore, most of the companies 
feel that data should be released for low price or even free of charge. On the other hand, some 
experts feel that releasing data without proper payment prevents a viable operating 
environment and markets from being developed.         
 
Table 3. Bottlenecks and challenges hindering data-driven precision medicine.  
Bottleneck / challenge Primarily affected 
stakeholders  
Description  
Healthcare 
Lack of clinical guidelines, 
education and decision 
support systems.  
 Genome test 
interpretation  services 
 Healthcare providers 
Clinical guidelines and education concerning the use of 
new methods and technologies in healthcare are 
missing, which decreases the use of genetic tests in 
healthcare (e.g. pharmacogenomics). Embedding 
guidelines in decision support systems would help the 
clinicians.  
Research evidence  is missing  Genome test 
interpretation  services 
 Healthcare providers 
 
Research evidence on the benefits of genome tests and 
new pharmaceutical products would be needed in order 
to motivate their use and related costs in healthcare.   
Genome testing services 
missing 
 Healthcare providers 
 
High quality genomic profiling and results interpretation 
services for cancer care are missing from Finland and 
services need to be searched from international 
markets.    
Public healthcare providers in 
Finland are slow in adopting 
new technologies 
 All companies 
developing new 
healthcare applications 
and devices  
Hospital districts and municipalities do not invest in 
adopting and piloting new products and technologies.  
Pharma 
Slow drug reimbursement 
decisions and regulatory 
approvals 
 Pharma companies 
 
Drug reimbursement decisions and regulatory 
approvals take too much time. This increases drug 
development costs and causes RWE studies to be 
done in many cases outside Finland.   
Biobanks 
Motivating donors  Biobanks 
 
Finland has a reputation that citizens are good donors 
of samples and data.  Motivation of the donors should 
be better maintained. For example, FinnGen should 
offer genome analysis results for the donors. It was 
pointed out, that a biobanks' "donor portal" is already 
being planned.  
Biobank consent   Biobanks 
 
Opt-in approach for biobank consent is inefficient and 
laborious. Opt-out consent would allow faster and more 
efficient data collection for biobanks.   
Biobank co-operative   Biobanks The Finnish biobank co-operative (FINBB) currently 
leaves out private biobanks. This is unfortunate 
concerning biobank co-operation and because public 
monopolies should be avoided. The role of FINBB is 
still unclear with respect to the services provided by the 
individual biobanks.  
SME companies 
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Bottleneck / challenge Primarily affected 
stakeholders  
Description  
Companies are not paid for 
data they collect from the user.  
 SME's providing health 
monitoring solutions.  
SME's are expected to connect their systems with 
centralized services (e.g. Kanta PHR) and to enable 
monitoring data to be used by other services. SME's 
are reluctant to release data without compensation.  
Participation of SME's in 
FinnGen is considered difficult  
 SME's 
 
FinnGen has taken the perspective of big pharma 
companies and academic research. There are not 
many real opportunities for SME's to co-operate.  
Lack of co-operation between 
SME's and large companies in 
Finland 
 SME's 
 
The amount of large companies in healthcare and 
pharma sector in Finland is small. It is difficult for SME's 
to find markets and to initiate co-operation with large 
companies to create successful products.  
In-house development of 
software in public sector  
 Companies developing 
healthcare applications 
Companies feel that public sector organisations should 
not develop SW in-house. Instead, they should co-
operate more with industry and adopt existing solutions 
of companies.  
Risk of over-pricing data  Companies If access to data is over-priced the interest of 
companies (especially SME's) may drop.    
Data access 
Access to data is slow and 
unpredictable 
 Research service 
providers and other 
direct data users  
 
The service processes of register-owners and biobanks 
is slow. Especially, large international pharma and 
medical device companies need fast and predictable 
access to data resources. If this can not be provided in 
Finland the studies will be executed elsewhere. Also it 
would be important to access more detailed level data 
than currently made possible in FinnGen.  
Centralized services for data 
access are still missing 
 Research service 
providers and other 
direct data users  
Despite of the centralized services, it seems that data 
remains distributed and difficult to exploit still for some 
time. Also, the division of responsibilities between the 
centralized and biobank-level services remains unclear 
and it is not yet clear which data resources will be 
available through centralized services (for example 
there is interest towards the hospital data lakes and 
primary healthcare data).           
It is difficult for companies to 
access data  
 Companies (including 
private healthcare)  
 
Availability of individual level data is restricted for 
scientific research. SME's do not have the required 
competences and resources and can't afford to use the 
help of research service providers. Furthermore, data 
access conditions are more strict for private healthcare 
than for public healthcare researchers.  
Personal data should be better 
exploited. 
 Healthcare providers 
 Pharma companies 
 Food industry 
 
The usage of personal health data (apart the normal 
clinical data) is not in-built in the healthcare process 
and only used in the minority of cases. Personal health 
data has growing importance also in clinical research. 
Nutrition research would benefit from detailed lifestyle 
data. A cost-efficient consent mechanism is needed.   
Healthcare data not in 
exploitable form 
 Research service 
providers and other 
direct data users 
  
A large part of data in patient information systems is in 
free text and therefore difficult to exploit. Secondary use 
is properly taken into account in quality registers, but 
these have not been developed fast enough as 
compared to other Nordic countries.   
Inclarity of regulation   Research service 
providers and other 
direct data users 
  
Legislation (Secondary Use Act, Biobank Act and 
GDPR) leaves open how data can be used ('scientific 
research' vs. 'data use for development and 
innovation'). There are no common criteria for 
anonymisation in use.  
Public policy 
Public funding for R&D and 
infrastructures decreasing  
 All companies 
 
Public funding for R&D and infrastructures has been 
decreasing. Finland should focus public funding in 
selected areas to increase impact.  
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Bottleneck / challenge Primarily affected 
stakeholders  
Description  
Risk that data is released for 
large international companies 
without proper compensation 
 Finnish companies.  
 Biobanks 
 
It is not considered appropriate to release data without 
proper compensation. Instead, results derived from the 
data should be offered. The interests of Finnish 
companies should be taken into account appropriately.   
Lack of coordination in 
standards and platforms 
 All companies 
 
Efficient use of data is only possible, if information 
systems (e.g. hospital data lakes) are connected via 
standard interfaces based on international coding 
systems and vocabularies.    
Lack of competences in 
specific areas 
 All companies 
 
There is a lack of experts with competences e.g. in data 
analytics, simulation techniques and epidemiology.  
 
5.5 FinnGen opportunity  
In all interviews, the FinnGen project was brought into discussion with the objective of 
understanding its importance for companies. As expected, FinnGen project was seen most 
useful by the pharma companies, especially those participating the project, but also others, 
which will have the possibility to use FinnGen data via add-on projects. Some Finnish SME 
companies were involved in the project, e.g. providing software platform components, and 
found the project beneficial for them. Otherwise, the companies outside FinnGen could not see 
direct benefit for themselves, although the project in itself was mostly considered to be positive 
and to bring good visibility for Finland.  
Some SME's had ideas for contribution in FinnGen in enhancing the connection between the 
project and the donors. An opportunity was seen in offering the donors a views for their genome 
data, personal risk factors and pharmacogenomics analysis results. Such activity would be 
highly important in bringing value to individuals and in motivating more people to join the project 
as donors. So far, such service have not been implemented.  
5.6 Stakeholder views on secondary data use  
The interviews raised interesting company perspectives on data-driven precision medicine. In 
general, most interviewed companies were expecting to benefit from the availability of 
individual-level data in some way. As expected, the pharma industry had most concrete ideas 
on data exploitation, and many of the companies already had experience on biobank research 
as well as using data from hospital data lakes. Especially RWE studies were mentioned as an 
important application area both by the pharma industry and by research service providers. 
Potential benefits of secondary data were also identified for the healthcare area, but the related 
business cases are not yet very clear. By default, public and private healthcare providers focus 
their resources in providing healthcare services using evidence-based clinical methodology. It 
seems, that especially in the public healthcare, there are not resources for experimenting new 
innovative methods in co-operation with companies. In private sector, there seems to be more 
activity towards exploiting data analytics to support care provision. Especially, the occupational 
health domain offers interesting new business opportunities.  
An interesting observation is that healthcare providers are primarily interested in accessing 
their own data repositories. Wider access to health data is 'nice to have' but not a priority, 
especially if excessive efforts are needed. This perspective is manifested by the rapid 
emergence of hospital data lakes as well as in the development of in-house data-driven 
solutions to support occupational health. 
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6 Company perspective to data exploitation   
Based on the interviews and informal discussions it is clear that availability of individual-level 
data for secondary use has a positive impact to society in several ways. Most evidently, 
positive impacts are seen in academic research and drug development where studies can be 
based on larger subject groups with individuals characterized by rich genotype and phenotype 
data. Besides pharma industry, also other business domains such as healthcare services, 
medical device manufacturers and food industry, are foreseen to gain from secondary use 
data. Moreover, there is a growing number of companies providing products and services to 
support data exploitation.  
Based on the interviews and informal discussions with stakeholders the objective of this 
chapter is to clarify the overall operating environment and the conditions under which 
secondary use of health data is possible for companies.  
6.1 Operating environment 
The operating environment for health data exploitation is depicted in Figure 2. Four main roles 
with respect to data exploitation have been identified: (1) data controllers, (2) data users, (3) 
research service providers and (4) service and technology providers.  
The organisation roles and their relations are described in the following subsections. It is 
important to note that in Figure 2 one company may appear in several roles. For example, a 
pharma company is in the role of data user when using services of research service providers. 
On the hand, the research service provider role may also be covered by the pharma company's 
internal research unit.  
 
 
 Figure 2. Operating environment for health data exploitation.  
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6.2 Data exploitation roles  
6.2.1 Data controllers and brokers 
Data controllers and brokers refer to centralized data operator services (FINBB or Service 
Operator) as well as individual biobanks and other data controllers which possess health data  
available for secondary use. As described in Section 3, the centralized services are still under 
development and in the current state data is obtained for research through the data controllers 
directly. These include the biobanks and all other organisations responsible for maintaining 
data registers, e.g. KELA, THL and Statistics Finland. Also health service providers are data 
controllers and may directly disclose data for secondary use. The legal framework for providing 
access to data and/or samples from biobanks is established by the Biobank Act. 
Correspondingly, data from the Service Operator will be accessed under the terms provided in 
the Secondary Use Act.  
As permitted by the related legislation, the three main approaches for user consent are (see 
Figure 2): 
1. Data use with specific consent by the data subject  
2. Anonymised use of data (without specific consent) 
3. Data use for scientific research (without specific consent) 
 
In Case 1, a specific consent shall be requested from the data subject, after which 
corresponding use of the data is allowed and is not limited to scientific research. The challenge 
of this model is that it is extremely difficult to collect specific consents especially from large 
groups of individuals. Therefore, it is not foreseen to be a viable approach for most of the 
anticipated secondary use scenarios. 
In Case 2, the data controller or broker carries out the anonymisation of the data to be 
disclosed. Also, in this model, the usage of data is not limited to scientific research and can be 
used for a large variety of innovation and development purposes as well as for monitoring 
organisational processes and quality. The challenge in this model is that it is extremely difficult 
anonymise data properly. When the disclosed data sets are large and contain several 
individual level health parameters, it is highly likely that persons can be identified. 
In Case 3, the data is used without specific consent, but shall be carried out according to 
scientific research practices. This is the prevailing model used in biobank research, where only 
a generic consent is required and in registry based research where no consent is required. 
Following scientific research practices implies that a research plan with valid research 
objectives need to be documented and results shall be published.  
6.2.2 Data users 
Data user refers to companies using data directly in-house or indirectly via research services. 
In the latter case the data user is not directly accessing the individual-level data, but merely 
data analytics results, aggregated data and visualisations.   
Currently, direct exploitation of health data mainly takes place in pharma and diagnostics 
companies. Data accumulated in healthcare registers is useful on one hand in the early phases 
of drug development, when identifying patient groups for new drugs and studying the related 
disease mechanisms. On the other hand, health data is needed in Real World Evidence (RWE) 
studies targeted to monitor the efficacy of pharma products.   
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As indicated in Figure 2, several other groups of companies besides pharma and diagnostics 
companies are potential information users. There is a growing number of companies providing 
services related to genetic testing. Business to consumer (B2C) and Business to business 
(B2B) services offer genetic tests and related interpretation and guidance. Typical examples 
are health risk analysis (B2C) (Su 2013) and pharmacogenomics assessments (B2B) (Brown 
2017). Such services are based on clinical evidence (published scientific knowledge). Access 
to data enables building this evidence and monitoring of the performance of the provided 
service.                             
For emerging value-based healthcare it is important for healthcare service providers to monitor 
the efficacy and quality of the healthcare delivery process. Monitoring is based on secondary 
use of patient data. This is especially relevant when new interventions, drugs and care models 
are adopted to clinical practice. A good example is the use of genetic tests in order to support 
care planning and decisions on medication.        
Healthcare information systems and medical device manufacturers are increasingly 
accompanied by artificial intelligence based software components providing advanced 
functionalities, such as clinical decision support. The development of such components 
requires health data to be available for model tuning and verification purposes. Also, data 
repositories can be used in assessing the number of certain types of patients, which may be 
important information in product development.  
Insurance providers have various types of information needs. An important area is insurance 
pricing. The usage of individual-level health data in pricing would not be ethically appropriate. 
However, aggregated health data could reveal, for example, health differences depending on 
living area, which could be taken into account in pricing. 
6.2.3 Research service providers  
Research service providers have the required capabilities of carrying out scientific research 
studies. In addition to specialized companies, this kind of services is traditionally provided by 
universities and research institutes. This role is important, since scientific research 
methodology is a pre-condition for using individual-level data without consent as indicated in 
Section  6.2.1.  Many of the companies in data user role do not have the required competences 
and prefer not to commit themselves to data analysis activities using scientific research 
methodology. Instead, they may prefer to outsource these activities to research service 
providers, which are expected to provide key results in a clear and directly usable form. 
Research service providers  are currently serving mostly the pharma industry. However, it is 
anticipated that this role needs to expand in the future to better serve the wide range of 
information users as depicted in Figure 2. Based on the interviews it seems clear that the group 
of data users is rapidly growing and getting more heterogeneous. As a result there is a growing 
need for versatile research services addressing not only the needs of pharma companies, but 
also the other business areas, such as healthcare services, medical device manufacturing and 
food industry.   
6.2.4 Service and technology providers  
Service and technology providers are a heterogeneous group of companies supporting data-
driven precision medicine. By default, large amounts of data are involved leading to the need 
for specific data management services. In many cases also the services of specialized data 
analytics companies as well as software providers are needed. In the case of biobank 
research, there is often a need for various types of laboratory and analysis services targeting 
a specific area of interest, such as genomics, proteomics and metabolomics jointly referred as 
omics.  The expanding activities around data exploitation is expected to increase the demand 
for service and technology providers.  
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6.3 GDPR considerations 
While potential business benefits of releasing data for secondary use are clear, it is important 
to take into account privacy and other fundamental rights of the data subjects (Ayday 2015). 
Secondary use is particularly critical, since in many cases it is not possible to obtain explicit 
consent from the data subjects. This is the case especially when analysis of large data masses 
is needed. As noted in Section 3.4.1. the usage of data without explicit consent is in line with 
the GDPR when the data is used for scientific research or when the data is fully anonymised. 
Anonymisation may be a feasible solution for data sets, which contain only a limited set of data 
for each individual and where rare phenotypes are not present. When a large spectrum of 
individual-level data is handled, full anonymisation is often not possible or it would require a 
substantial amount of information to be removed from the data set. The challenge is expected 
to become even more prominent in the future as the dimensionality of biobank data grows 
(Polašek 2013).     
Due to the inherent problems of full anonymisation, it seems that the scientific research 
approach is most appropriate in many cases. This approach is attractive also because the 
GDPR adopts a broad definition for 'scientific research' covering also 'development and 
demonstration of technology'. On the other hand, the broad definition leaves open, what 
actually can be included under the term1.  Unfortunately, the current draft of the complementary 
national privacy legislation2 does not include a clarification for the definition of 'scientific 
research' either. The draft Secondary Use Act3 explicitly defines the term 'development and 
innovation activity' as an application area for secondary use on the condition that explicit 
consent is given by the user.         
Evidently, detailed conditions for accessing data are not yet clear and probably different 
interpretations of the GDPR will be seen in different EU countries. For the time being, the best 
guess is that without explicit consent, individual-level data will be released for studies carried 
out using scientific research methodology. This requires that a valid research question needs 
to be formulated and a corresponding research plan needs to be presented by the data 
recipient. There may also be requirements to publish the study results. In any case, the 
recipient of the individual-level data becomes the controller of the data set and needs to ensure 
GDPR compliancy in managing the data set and in ensuring the rights of the data subjects. 
Pseudonymisation of the data does not free the data processor from the obligations stipulated 
by the GDPR (Chassang 2017).    
The responsibility for managing and processing individual-level data sets can only be taken by 
organizations, with the required competences, processes and information systems. Pharma 
companies typically have such capability. Additionally, such services are provided by 
specialized SME's, universities and research institutes. Taking into account the growing 
importance of health data for pharma development and other business sectors, it is clear that 
the demand for research services will grow. Especially, the new emerging data users, such as 
healthcare providers, medical device manufacturers and food industry need external services 
in order to exploit individual-level data. In typical scenarios, companies have research 
questions related to their product development and marketing. They need answers to the 
questions, but are not willing to invest their own resources for carrying out the actual research 
activity. 
As discussed above, access to individual-level health data will remain strictly controlled even 
if improved processes and platforms enabled by centralized services as described in Section  
3.3  are expected to enable more efficient and predictable access to data. 
                                               
1 https://www.law.kuleuven.be/citip/blog/scientific-research-under-gdpr-what-will-change/ 
2 https://www.finlex.fi/fi/esitykset/he/2018/20180009 
3 https://www.finlex.fi/fi/esitykset/he/2017/20170159 
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7 Artificial Intelligence Opportunity  
7.1 Artificial Intelligence use cases 
From Artificial Intelligence (AI) technology point of view, the interviewed stakeholders pointed 
out many topics of interest. Due to the large variety in business fields and company profiles, 
the found AI-related topics covered a broad range of use cases and application areas. Table 
4 summarizes these application use cases and related technologies.   
Table 4. Application use cases with AI potential1 
Application use case Related technologies and AI options 
Online health services, Virtual Clinic, eHealth 
services 
chatbots, data integration, intelligent visualization, 
intelligent sensor data processing, data fusion, NLP, 
DSS, ML, NN 
Virtual coach; Questionnaire based mobile app 
with recommendations for maintaining health 
and medicine usage 
large database handling, suggestion engines, natural 
language processing 
Digital interventions, companion app; 
intelligent applications to support medicine 
usage and increase adherence 
DSS, data integration, free text interpretation 
Continuous detection of unhealthy lifestyle and 
preventive actions, providing adaptive 
personalized feedback 
multi-domain personal representations, profiles, 
lifestyle ‘fingerprints’, ML, traditional clustering 
methods, time-series analysis (LSTM) 
Intelligent support for use of medicine and 
integration of care process in combination with 
e.g. lifestyles, demographic background   and 
use of medicine 
DSS, data integration, natural language processing, 
intelligent visualization, intelligent sensor data 
processing, data fusion, clustering, high-dimensional 
data exploration, understanding, exploitation 
Personalized analytics for (occupational) 
health 
data integration, understanding, exploration, DSS, 
time-series prediction 
Personalized services for patients with severe 
illnesses  (e.g. cancer, trauma).  
data integration, understanding, explication, 
intelligent visualisations 
Data exploration from complex data combined 
from health and other domains 
DSS, multi-domain classifier, ML, DNN 
Utilization of self measured health information 
and use of it with traditional health care data. 
MyData approach and data fusion 
Image processing for medical data Image segmentation, automated measures and 
feature extraction, ML, DNN, CNN, traditional 
algorithms 
Update of clinical guidelines using AI methods 
based on medical findings and known 
literature. Using wider perspective efficiently in 
health care. 
DSS, data integration, free text interpretation, ML, 
DNN, NLP 
Finding new use targets for existing medicines. simulations, cohort detection 
Early-failing in drug development with help of 
genetics. AI helping to detect the harmful 
genes and/or efficient medicine. 
simulations, cohort detection, classifiers, clustering 
                                               
1 AI = Artificial Intelligence, NLP = Natural Language Processing, NN = Neural Networks,  
ML = Machine Learning, DSS = Decision Support System, DNN = Deep Neural Networks,  
CNN = Convolutional Neural Networks, LSTM = Long Short Term Memory, DL = Deep Learning 
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Application use case Related technologies and AI options 
Support for fast cycle medicine development 
(6-8 months), cohort detection and selection, 
Preclinical studies for medical treatment based 
on genetics. 
classifier and clustering, time-series analyses 
Risk prediction at personal, meso and 
population level from genomic, lifestyle and 
demographic data 
classifier and clustering 
Impact assessment, taking objective pros and 
cons of interventions into account in decision 
making 
DSS, data integration, natural language processing, 
intelligent visualization 
Large scale market segmentation of insurance 
customers 
classifier and clustering, ML, traditional clustering 
methods 
Preventive forecasting for life insurances, risk 
assessment 
classifier and clustering, ML & NN 
 
 
Specific areas of interest for AI applications can be detected from Table 4. The first one is the 
eHealth service related ideas to bringing clinicians in contact with patients via computers or 
mobile devices. These services can speed up the contact to all patients while only severe 
illnesses require actual visit to hospital. Virtual AI-based assistants can provide automatic 
feedback and decision support e.g. for chronic disease patients at home thereby enabling 
independent self-management of the disease. In more severe cases, even real-time  
surveillance with AI-based detection of the deterioration of the patient condition can be 
achieved. For such applications, predictive models based on large data sets on earlier patient 
cases are needed.   
The second clear interest area concerns drug and medicine based therapy development. The 
data with AI technologies could enable faster drug development and better cohort detection 
for drug tests. It could also enhance drug based treatments when the drug to be used could 
be selected based on genetics (pharmacogenomics) or cohort based knowledge. Less try outs 
would be needed to identify the best possible drug treatment for the patient.  
The third interest area is personalized services for healthcare and health maintenance, e.g. 
provided by occupational health providers or insurance companies. Such approaches are 
based on holistic understanding of the individual's health status and how it can be best 
supported with available resources, including both legacy healthcare services and eHealth 
services. AI technologies provide various tools to implement such applications, but significant 
amount of data is needed to create reliable results. 
7.2 Potential technologies 
The previously identified topics include opportunities for various AI related technologies, where 
the greatest challenges are related to the data access and quality. As a single topic, AI is 
extremely wide and it is better to consider AI technologies as an umbrella which includes 
various methods under it. Often AI refers to machine learning (ML) methods or neural networks 
(NN) with deep learning (DL) approaches (Meyer 2018). The greatest modern advances with 
AI titled technologies are based on deep learning methods, which can be considered as one 
type of machine learning with neural networks. Common to all of these are that they need a 
large amount of well curated data. 
Recently, natural language processing (NLP) has been used in many application areas, 
including healthcare. A typical NLP application is the interpretation of natural language with 
NN methods using DL approaches. NLP is a convenient tool for processing non-structured 
contents such as free text reports or user feedback. This type of data is abundant in healthcare 
settings. More advanced approaches use NLP to create chatbots to homepages or social 
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media platforms. Chatbots are successfully used e.g. in healthcare service provider settings, 
to answer simple questions, and help with making reservations for appointments. In recent 
approaches, NLP technology is typically combined with speech recognition and synthesis, 
which has enabled assisting technologies like Amazon’s Alexa1 or Apple’s Siri2. In practice, all 
big cloud providers have their own implementation of these technologies.  
The current development in cloud services has brought basic AI technologies within reach for 
every company and even for individual developers, without needing in-depth knowledge about 
AI technology and paradigms itself. All major cloud providers have their own pre-trained APIs 
for users to utilize text, image, sound and video recognition services: 
 IBM BlueMix Watson3  
 MS Azure AI4 
 Google Cloud AI5 
 Amazon AWS Machine Learning6 
 
The pre-trained API's with low costs enable a large variety of basic analytics to be implemented 
in different services without virtually any cost for AI development. In practice, the case is not 
simple as the processing of health domain data involves significant security and privacy 
requirements. This typically causes limitations for using commercial APIs. Often it is needed 
that the computations are ran on the premises where the data physically resides or, more 
typically, on virtual private networks (VPN) with no connection to the public Internet. Another 
trend is calculation within devices (e.g. mobile phones) and only provide summarized data to 
the outside world (edge and fog computing) (Chen, 2018). 
An obvious question concerns the decision between developing an AI or ML system in-house 
to create a custom application and using existing commercial APIs. There is no single answer 
for this, but one significant challenge is data and system security. Many data controllers want 
to ensure that all data processing happens inside Europe, which can reduce the options to use 
commercial APIs. Furthermore, for security reasons the data controllers may not allow data to 
be processed outside their own network, which also causes limitations for the use of 
commercial APIs. Cloud providers have options to create secure VPN environments for this 
kind of cases, but it requires custom work to set up such processing environments. Another 
side is accuracy, if the data is specific for a certain group and the case is not common it is 
almost mandatory to create a custom AI solution for the case.  
One significant challenge in data utilization is the GDPR, which implies the need for 
anonymisation in many application areas. When data is fully anonymous the GDPR does not 
apply. The challenge is that even when the data seems to be anonymous, it may still be 
possible to identify individuals by combining the data with other data sets. When using large 
datasets with a high number of measures and variables it is hard to confirm that ML methods 
cannot identify single individuals from the data. For this reason, many new privacy preserving 
methods are under development. For example, Google researchers have proposed an ML 
method where a model is trained in portions and at the end, the partial models are combined 
as whole model without any original data. 
                                               
1 https://developer.amazon.com/alexa 
2 https://developer.apple.com/sirikit/ 
3 https://console.bluemix.net/catalog/?category=watson 
4 https://azure.microsoft.com/en-us/overview/ai-platform/ 
5 https://cloud.google.com/products/machine-learning/ 
6 https://aws.amazon.com/machine-learning/ 
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7.3 Future opportunities 
The use of AI technologies are in a transformative state. During the previous AI hype it was 
believed (by some) that many areas of medical work, such as analysing radiological images, 
could become entirely automated by AI technology. Currently, the consensus is that AI merely 
relieves time-consuming routine work and supports human users to make better decisions and 
to perform more precise work faster1.  For example, Google researchers released their article 
stating that AI will not replace the human doctor, but can assist them to make better decisions 
(Li  2018). Most of the specialists in AI related fields have agreed this already for a long time 
and in practice most of the current AI applications are actually supporting the human actions. 
The better term for artificial intelligence would be assisting intelligence, or augmented 
intelligence, sometimes referred as IA, (Intelligence Augmentation/Amplification) (Jarrahi, 
2018).   
AI solutions can be better than human equivalent when the task is limited (narrow intelligence 
is needed) and variance within the cases under the task are within certain limits. Detecting 
details from images or expressions from texts are this kind of tasks (Li 2018). A natural 
continuation for this process would be systems which combine various AI technologies in 
series and parallel setups to create more complete picture from the case under investigation. 
Even in these cases, the main aim would be to enable human specialists to use more time in 
actual work instead of manually collecting and interpreting increasing amounts of information. 
In the application use cases listed in Section  7.1 there are clear examples where AI can speed 
up processes and help to make more accurate decisions in health domain. NLP technologies 
could be used to structure the information content and even create clinical data classification 
from free text descriptions. Also free text entries in Electronic Health Records can be translated 
to coded structural information. On the other hand, the same approach could also be used to 
generate a written standard report from basic medical imaging cases. The intelligent system 
could first segment the image and then measure standard measures form the segmentation. 
When going further on this direction the machine learning system could even try to predict the 
outcome of the patient based on data given as input. One example has shown by the Google 
researchers with chest x-ray imaging algorithm2. The first deep learning powered medical 
image processing tool from Arterys is another good example3. In each of the cases the doctor 
would check the results and approve them before they would be used in clinical practice.  
One interesting topic for the health domain is user group segmentation to identify patients, 
which need more attention and monitoring than average patients. An advanced AI application 
case would include optimization of the healthcare path through primary care, hospitals and 
homecare aiming at improvement in terms of healthcare quality and cost-efficiency. This would 
be possible with a wide enough view to the healthcare system and good modelling of different 
care paths throughout the healthcare system. Clearly, these cannot be solved with a single AI 
method, but they need a well tested system utilizing multiple methods.  
A similar challenge to the healthcare path optimization is within drug development and usage. 
With large data sets and proper AI methods it would be possible to identify which drugs are 
most suitable to different individual patients based on their treatment history, demographics 
and genetic burden. This would enable the precision medicine approaches in drug therapy and 
could be combined with lifestyle changes supported by AI powered coaching tools. AI 
technologies can also support remote care by monitoring a rich combination of data from the 
patient during daily activities and vital signs at home and when needed give a warning to the 
health care personnel to check the status of patient early enough before the health status of 
the patient is getting down. In this kind of scenario the system would need both real time 
                                               
1 MIT review: Google x-ray project shows AI won’t replace doctors any time soon 
2 HealthImaging: Google AI algorithm may improve chest x-ray interpretation, radiologist efficiency 
3 PR Newsware: Arterys Receives First FDA Clearance for Broad Oncology Imaging Suite with Deep 
Learning 
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measurements but also the patient history and some classification what kind of signs are 
emphasizing the risk. Humans can monitor single cases on these kind of systems but manual 
observation of various real-time signs is challenging. 
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8 Business strategies  
In this chapter we identify and analyse emerging opportunities for precision medicine related 
products and services and develop recommendations for business strategies and public policy 
measures to accelerate formation of a dynamic business ecosystem in Finland.  
Four opportunity areas have been identified from existing research literature and market 
studies:  
1. Development of new therapies  
2. Health risk assessment and diagnostics   
3. Selecting therapy  
4. Direct-to-consumer genomics 
 
Each opportunity area covers value creation functions that precision medicine applications 
may provide to patients, consumers, businesses and society. Value is a benefit or positive 
impact to user which may be created through various functions: for instance, improving health 
impact of treatments, more efficient and precise identification of diseases and health 
conditions, acceleration and streamlining of drug development, or provision of wellness related 
information that consumers are willing to pay for.  
For each opportunity area we analyse demand conditions and to whom the value will be 
potentially created. Value may be generated to individual patients or consumers, healthcare 
organisation, or companies such as pharmaceutical industry. Products and services can, to a 
large extent, be organized in value chains. For example, a medical device manufacturer 
provides a genotyping or sequencing technology to a diagnostic service provider, which 
performs genomic tests to health care organisations (public or private) providing clinical care 
to individual patients. Between each customer and provider (seller and buyer) there needs to 
be a reasonable proposition where the value of product meets the customer’s willingness to 
pay.  
In many cases it is also likely that value can be distributed between several types of actors. 
For instance, a pharmacogenomics test service might improve patient health by reducing 
adverse drug reactions while simultaneously creating savings for the healthcare organisation 
by avoiding provision of extra treatments to deal with undesired side effects. Value creation 
has, in these kind of cases, systemic properties which extend beyond one-to-one relationship 
between user and supplier. The systemic value creation potential is particularly large for data 
which can be used by several users for various purposes and combined with other data 
multiple times without its value being lost. Data sharing capabilities are thus of particular 
interest for this analysis.  
Third, we review supply of new products, services and solutions which claim to deliver the 
proposed value. The review is based on analysis of existing and recently introduced products 
and services, as well as emerging new solutions for which information is publicly available (e.g. 
scientific publications reporting results from ongoing trials). The review does not aim to be a 
comprehensive overview of all relevant products and companies currently active in this 
enormous field. Instead, we present examples of interesting cases on emerging technologies 
and new business models.  
The fourth element in our analysis is drivers and barriers for market creation, value generation 
and business growth. Drivers may range from economic factors (e.g. cost-effectiveness, high 
cost of treating chronic diseases) to topical trends (e.g. consumer preferences) and social 
factors (e.g. safety, privacy). As for barriers we aim to identify bottlenecks which hamper 
business growth such as factors which are curbing down latent demand (e.g. lack of high 
quality evidence or missing clinical guidelines), reducing market scalability (e.g. lack of data 
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interoperability), or hindering and slowing down market evolution (e.g. regulatory requirements 
not keeping pace with fast developing market developments).  
Each section concludes by a discussion on possible business models and by proposing 
business strategies and public policy measures to accelerate business growth and value 
capture for Finland. These may include removal or lowering of identified barriers (e.g. 
regulatory reforms), setting up shared resources (e.g. data platforms), or improving 
preconditions for collaboration in research and development.  
8.1 Development of new therapies  
Perhaps the most obvious opportunity area for precision medicine is development of new 
therapies, particularly novel pharmaceutical drugs. Collection and analysis of genomic and 
other omics data has the potential to generate several benefits to new drug development 
process. It may allow more precise targeting of research efforts and accelerating finding of 
novel mechanisms and associations thus reducing R&D costs. Data may enable more precise 
patient stratification for clinical trials speeding up the process and reducing costs. According 
to some estimates genomic information used in identifying target molecules could double the 
success rate of drug discovery process. Data can also be used to control for the response of 
drug therapies with different populations around the world. Large opportunities are assessed 
to be gained when genomic data is combined with other health data such as clinical data 
describing phenotypes and treatments. Electronic health records (EHRs) contain relevant 
information to be used for establishing new patient stratification principles and identifying 
disease correlations (Jensen et al. 2012). Detailed phenotyping is expected to contribute to 
patient recruiting for clinical trials, and over time, start automating the recruiting process. 
Linking genetic data with other health data offers thus large untapped opportunities for new 
drug development.  
The opportunity of using health data in development of new products actually extends beyond 
the pharma companies. The food industry is increasing efforts towards developing 
personalized food products with favourable effects on health. Such product development can 
also get considerable benefit from the access to genome, microbiome and phenotype data.  
Demand. The demand landscape is divided in two distinct stages along the value chain. First, 
pharmaceutical companies source various technologies and R&D services to support the drug 
development process. These include genomic sequencing and genotyping devices and 
services, bioinformatics, software, computing, analytics, and research services to manage 
clinical trials. Second, once a new therapy has been introduced on the market its demand is 
conditioned by regulatory approval, therapeutic and cost-effectiveness assessments and price 
negotiations with reimbursing organisations. The final demand is hinging on approval from 
healthcare providers and reimbursing organisations, whose awareness of new therapy 
opportunities and their clinical impacts affect speed of uptake.  
Supply. Data can be supplied by non-commercial and commercial sources as described in 
Section 4.4. Public or not-for-profit biobanks and large-scale research projects generate non-
commercial sources of data. A current trend in the medical research is formation of pre-
competitive research communities (Palotie & Ripatti 2017). The communities undertake 
research projects without commitments to immaterial property rights. These sources are 
expected to provide a wealth of relevant data for precision medicine discoveries and 
applications.  
Commercial sources of data are private clinics, some of which have established their own 
biobanks, and specialised data providers. Also companies offering direct-to-consumer genetic 
testing services have been making contracts with pharmaceutical companies about genetic 
data provision for R&D purposes.  
 
              45 (75) 
 
 
 
A variety of business opportunities for firms are available in supplying research services to 
pharmaceutical companies performing drug development projects. There is demand for 
contract research organisations (CRO’s) specialising in genome-based research, data 
analytics and interpretation services, as well as information systems (Palotie & Ripatti 2017).  
In the technology space, the market leaders in advanced sequencing technology are Illumina 
and Thermo Fisher. In addition, there are several smaller companies engaged in the 
technology development race. An interesting opportunity is the supply of data management 
platforms. This involves integration of genomic data, other omics data, and data retrieved from 
operative healthcare information systems. BC Platforms and BCB Medical are promising 
Finnish companies in this market segment.  
New business models are experimented by companies which compensate individuals for 
licensing their genomic data to pharmaceutical companies. Genos, based in San Fransisco, 
provides a service to sequence its customers’ exome for a reasonable price (399 US dollars 
in 2018). Customers can then license their genomic data and receive a financial compensation. 
The business model of Genos is thus not based simply on sale of genetic testing but rather 
brokering access to genetic information between individuals as data providers and companies 
as data users (Roberts et al. 2017).  
Drivers. The primary driver behind use of genomic data for drug development is the potential 
to find new therapies for hereditary diseases, new treatments for cancer, and many other 
severe diseases. Treatment of severe diseases is costly, creating a strong economic driver for 
up taking new drugs.  
An important technological enabler is the rapidly falling cost of sequencing. In little more than 
ten years the price of sequencing the whole human genome has come down from 3 billion 
during the Human Genome project to less than 1000 US dollars currently. The low price of 
sequencing makes it feasible to gather genomic data from a very large number of people. 
These kinds of initiatives are now taking place all over the world as described in Section 4.3. 
One of the large scale projects is the Finnish FinnGen which aims to collect genetic data from 
500 000 individuals. Investments in collecting massive genomic data sets in several flagship 
initiatives around the world are accumulating a wealth of data which drives research and 
development. Many of these sources operate under non-commercial principles which means 
that anonymised data is to some extent open for exploitation.   
Another major economic driver is the high cost of new drug development. A common estimate 
in the pharmaceutical industry is that development of new pharmaceutical therapy has an 
average price tag of roughly 1000 M€. Large part of the costs are accrued in the clinical trial 
stages. Any opportunities to shorten time to market are highly interesting due to the big 
associated financial benefits.  
Barriers. While there are very strong economic drivers for advancing precision medicine, there 
are still barriers, many of which are institutional and social by nature. The first is obtaining and 
managing patient consent for data gathering in reliable way, which meets regulatory 
requirements and satisfies people’s concerns about privacy. The second is combining genomic 
data with other health data which is still cumbersome as access to electronic health records is 
restricted and the data not readily in a usable form. Data integration also suffers from legacy 
information systems with limited support for interoperability standards. Third, there is shortage 
of highly qualified research service providers who can cater for more comprehensive research 
management needs of pharmaceutical firms.  
An economic issue has come up with many new drugs in the precision medicine space due to 
their very small target group of patients. New advanced drugs might target rare diseases 
having only a thousand patients or less in one country. The large R&D investments used to 
develop the drug and bring it on the market need to be charged from this small population of 
patients and their healthcare providers or insurers. Revenue should also simultaneously cover 
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expenses from other unsuccessful projects which did not exit from the R&D pipeline. Recent 
examples include blindness gene therapy by Spark Therapeutics with a list price of 850 000 
US dollars per treatment. Several earlier gene therapies (Provenge, MACI, Glybera, 
Chondrocelect) introduced on the market have been already withdrawn due to their limited 
commercial success.  
Business models. Development of new drugs sets challenges for conventional business 
models of pharmaceutical companies as many of the drugs target small populations of patients 
with rare diseases such as genetic disorders. Covering the high costs of R&D creates a 
pressure to charge very high unit price per treatment. Pharmaceutical companies increasingly 
argue for value-based care and outcome-based reimbursement models. Under this approach, 
high unit price are justified on the basis of the total value provided including e.g. other care 
costs avoided. At the same time, there are expectations that utilization of genomic data can 
bring down drug development costs, in which case the pressure to change the current business 
model would become less stringent.  
 
As for companies that are providing research services for pharma industry, there are numerous 
business opportunities to cater for their needs. Business models can be based on 
comprehensive research services to manage clinical trials, analyze associated data and 
provide real-world evidence. Or they can be provided as specific service inputs to the process 
on-demand basis.  
 
Bioinformatics, analytics and software solutions can be provided both as ’turnkey’ solutions or 
more targeted inputs to the client’s process. As internal capabilities of pharmaceutical 
companies vary, it is likely that various business models may thrive.  
 
In addition to public healthcare institutions also private healthcare service providers are 
establishing biobanks. They are exploring opportunities to become data providers to 
pharmaceutical firms. As an asset, they can combine other health data with genomic data from 
their registers. Whether this will become a viable business in the future remains to be seen.  
 
Policies and strategies. In order to overcome the barriers there are various policies and 
strategies that can be adopted and reinforced:  
 Regulation to permit and manage secondary use of health data; the respective laws 
processed by the Parliament of Finland will need to be accompanied by guidance in 
order to be efficiently applied in practice.  
 Establishing a one-stop shop for accessing data from biobanks either via FINBB or the 
Service Operator (the FINBB has been established, but does not yet have resources 
to establish such service).  
 Sufficient resourcing of the Service Operator enabled by the secondary use legislation.  
 Developing capabilities for big data management, bioinformatics, analytics, and 
artificial intelligence across all stakeholder groups involved; support to small and 
medium sized companies to specialise in these domains to serve pharmaceutical 
companies not finding it necessary to build that capability in-house.  
 Developing low cost patient consent management services (e.g. as API service)  
 Protocols and codes of conduct for sustaining privacy particularly addressing 
secondary use of health data.  
 Establishing and agreeing on standards for data interoperability including metadata 
and common data models supporting secondary use of data. 
 Fast and timely undertaking of cost-effectiveness studies and health technology 
assessments (HTA’s) to accelerate market access for new therapies.  
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 Development and use of outcome-based reimbursement models and systematic 
generation of associated outcome data.  
 
8.2 Health risk assessment and diagnostics   
 Access to genomic data provides opportunities to identify health risks and diagnose genetic 
diseases. Traditional genetic tests have been long available to find genetic diseases, many of 
which are rare in number among the whole population. Hereditary diseases, such as 
Huntigton’s disease, are typically single gene mutations which can be tested with targeted 
genetic tests. The modern next generation sequencing has become recently cost-effective to 
link person’s genotype with predisposition to illnesses or health conditions. This allows for 
identification of more diverse sets of risks across the entire genome.  
Demand. The demand for health risk assessment and diagnostics comes from multiple 
sources: public health care providers, private care providers, and consumers. Clinical 
diagnostic tests are typically ordered by a patient’s medical service provider. They are used to 
identify or rule out a specific genetic condition. One example is clinical diagnostics for the 
BRCA1 and BRCA2 genes affecting hereditary breast cancer and ovarian cancer syndrome 
(Tandy-Connor 2016).  
Comprehensive screening of populations or sub-populations by genotyping is not yet widely 
undertaken due to insufficient cost-effectiveness. For many diseases and health risks clinicians 
have conventional means to identify risks which have been found to be more cost-effective 
than genetic tests. These include queries about the family disease history and conventional 
measurements such as weight or blood tests etc.  
Supply. Examples of diseases for which genetic tests are available are breast cancer and 
prostate cancer. New genetic tests are becoming available also in Finland. An example is 
FinnScreen provided by Dextra which includes analysis of 40 Finnish genetic disease risks. 
The test is a ’carrier screening test’ intended for couples for controlling their risk for passing 
inherited disorders to their children. The test is designed for the Finnish population to cover 
the most common genetic disorders.  
Drivers. A technological driver is evolution of sequencing and genotyping devices from heavy 
laboratory facilities towards lighter and portable devices. It appears likely that the devices will 
soon enter point of care and thus closer to clinical settings where diagnostics can be quickly 
performed. An example of a company developing a hand held sequencing device is Oxford 
Nanopore from the UK. 
Another potential driver is accumulation of genomic data in data repositories and electronic 
health records. Once the genomic data becomes readily available its unit cost for reuse is likely 
to drop making it economically more feasible to use genetic data in clinical decision-making as 
one source of information. While the data is not yet widely available, it is likely that over time it 
will start accumulating and become available.  
A potential institutional driver could be provided by outcome-based healthcare financing 
models. The proposed transition in the Finnish healthcare reform towards capitation based 
financing model combined with outcome-based targets might create new incentives for more 
comprehensive screening of genetically-conditioned risks. Particularly for common illnesses, 
such as cardio-vascular diseases or diabetes, whose occurrence has a more complex 
association with genetic variation, more comprehensive responsibility of health status over a 
regional population could provide a driver for more systematic predictive testing.  
Barriers. A barrier to widespread diffusion of genomics-based risk assessment services is 
divergence of views over providing people with information about risks which might or might 
not actualise over a long time. Many fear it might create unnecessary agony for factors which 
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are not under person’s influence. It is likely that controversy around the topic will continue for 
some time. However, recent studies indicate that many people do appreciate information 
potentially impacting their future health conditions. This appears to apply also to children. 
According to one recent study a majority of adolescent children would prefer to know the results 
of unanticipated findings found in genomic testing even if the findings were not medically 
actionable until adulthood (Hufnagel et al. 2016).  
An economic barrier is prevailing doubts about the clinical utility and cost-effectiveness of 
comprehensive screening programs. In order to roll out comprehensive screening of population 
strong evidence is needed as cost-effectiveness remains an issue. Moreover, in some cases 
the association of genotype with a disease applies only for certain sub-population. Breast 
cancer is a case in point, as it has been assessed cost-effective only for people from particular 
ethnic groups (D’Andrea et al. 2016).  
Business models.  As the price of genetic tests and even comprehensive genomic 
sequencing continues to drop with high speed, diagnostic services are gradually moving closer 
to the point of care context. Medical device manufacturers’ revenue is increasingly coming 
from consumables and services related to operating devices.  In industry forecasts it is argued 
that sequencing the whole genome of a patient on a routine procedure by healthcare 
institutions is not very far off in the future. The data would be stored in electronic patient record 
and retrieved on-demand basis. This would create a large opportunity for genetic test 
providers. 
Policy and strategies.   
 Improve the evidence base to demonstrate the clinical utility of genetic tests with cost-
effectiveness studies.  
 Develop capabilities to use genomic data as one source of information and combine it 
with other health data in the clinical decision-making. Further investments on solution 
development are needed in order to create clinically sound results in more complex 
health conditions.  
 
8.3 Selecting therapy  
There is now increasing amount of evidence that a patient’s genetic profile may affect efficacy 
of drug therapies. There are currently at least 80 medications whose efficacy to treat specific 
disease has been demonstrated to be associated on patient’s genotype (Relling & Evans 
2015). Less than 20 genes out of all 20 000 genes have been found to be affecting drug 
metabolism. Unsuitable drug or incorrect dosing can cause side effects, which in some cases 
can be severe, even leading to death. In the United States it has been estimated that more 
than 100 000 deaths annually are caused by adverse drug reactions. In Germany 3.25 % of 
all hospitalizations are due to adverse drug reactions generating treatment costs of 434 million 
Euros per year (Plöthner et al. 2016). Controlling for patients’ genotype thus has a potential to 
increase drug therapy response, reduce adverse drug reactions and decrease health care 
costs.  
One of the first drugs with associated response depending on patient’s genetic profile is 
warfarin which is used for blood thinning. Varying response may lead to too low dosing for 
some patients and too high dosing for others. Both may have serious health consequences 
and cost implications.  
There is now a large number of diseases for which evidence has been generated: 
cardiovascular diseases, stroke, epilepsy, depression, high cholesterol, rheumatoid arthritis, 
tuberculosis, and various types of cancer. New findings are published in accelerating speed.  
In cancer treatment, use of genomic information extends beyond simple patient genotyping to 
genetic profiling of tumours. A majority of cancers are driven by genomic alterations that 
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dysregulate key pathways influencing cell growth and survival (Garraway 2013). Genomic 
information from individual tumours has the potential to improve clinical outcomes for patients 
with cancer.  
It is expected that point of care decisions will become increasingly customized to the unique 
genomic and proteomic features of a patient's tumour. One example is treatment of thyroid 
cancer for which identification of benign nodules with help of genomic data can avoid close to 
70 % of patients from unnecessary surgery.  
A highly specific use case for genetic data is controlling for genetic compatibility in organ 
transplantation.  
Demand. The conventional demand for genetic test diagnostics is related to pre-natal 
screening and various hereditary diseases. Many new discoveries concerning genetic 
predisposition to diseases and associations between genotype affecting metabolism and drug 
response are not yet expressed as tangible demand for genomic data and analytics. As 
demand is emerging for more advanced precision medicine solutions, the channels through 
which the demand will materialize as business opportunities for companies offering related 
products, will become more clear only in the future.  
Supply. The supply of services to cater for selecting the most effective therapy taking into 
account the patient’s genotype include stand-alone genetic tests, analytics and interpretation 
of data, data storage services, integration with electronic health records, and clinical decision-
support systems. In Finland there are several firms active in this space such as Abomics and 
Euformatics.  
Drivers. The overriding driver for applying genetic information for selecting the therapy and 
dosing of drugs is the potential to improve quality of care while simultaneously avoiding costs 
of dealing with adverse drug reactions or unresponsiveness to therapy. Potential for cost 
reduction provides a major impetus for applying pharmacogenomics data in clinical use.  
Barriers. Cost-effectiveness is not yet confirmed for all discovered associations between 
person’s genotype and response to therapy. Retrospective research would benefit also 
companies in their marketing efforts by providing evidence-based claims about the value of 
their products and services. However, technology development and market scale-up are likely 
to bring the unit cost down over time, improving the cost-effectiveness of pharmacogenomics 
tests in clinical use.  
Interesting findings were provided by Verbelen et al. (2017) who found out that for half of the 
cases in which association of a drug was associated with patient’s genotype, a related 
pharmacogenomics test was found cost-effective. Moreover, they concluded that when 
genotype information will be readily available at negligible cost from the electronic health 
records in the future, a clear majority of economic evaluations would support 
pharmacogenomics-guided treatments. In other words, once collecting genotype information 
becomes a standard procedure in the health care process instead of distinct on-demand 
service request, the cost-effectiveness of pharmacogenomics tests increases significantly and 
is likely to become a routine operation for most of the identified cases.  
Another hindrance is lack of care guidelines addressing the value of genetic data in relation to 
selecting the therapy and dosing (Heliste et al. 2016). Clinical guidelines are currently 
developed by a collegium of medical professionals on the basis of a selection process based 
on relevance assessment. While clinical guidelines can be powerful means to diffuse best 
practices across the medical profession, lack of guidelines may slow down adoption of new 
technology and practices.  
A barrier for business development based on supplying diagnostic and pharmacogenomics 
services to public healthcare is a tendency of some public healthcare institutions to develop 
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these capabilities in-house. Particularly for non-technological parts of the process, such as 
interpretation and counselling services, non-commercial practice emerging inside the 
healthcare institution, or by a subsidiary company established by a public hospital, can slow 
down market growth for private supplier firms operating on commercial principles.  
A further difficulty experienced by precision medicine solution providers is shortage of 
opportunities to pilot new solutions with public healthcare providers such as university hospitals 
and demonstrate the value of solutions. Some innovation platforms have been experimented 
recently, which might open up new possibilities, but practices are still unsystematic and 
opportunities mostly on ad hoc basis.  
Business models.  Using genomic information to guide selection of therapy and dosing of 
drugs creates need for decision support systems to assist clinicians whether a drug is suitable 
for a patient. Some providers seek close integration with healthcare and hospital information 
systems. Another ones provide comprehensive services to deliver test results commissioned 
by clinicians. As development of healthcare information systems with regard to 
pharmacogenomics is still in an early stage, it is early to assess which model is likely to prevail 
on the long run. Particularly in oncology it is becoming increasingly relevant to develop 
companion diagnostics which are tests used as a companion to a therapeutic drug to assess 
its appicability to a patient. 
 
Policy and strategies  
 Increase training and awareness raising among clinicians and health care practitioners.  
 Support and accelerate creation of clinical guidelines for pharmacogenomics tests and 
disseminate related information.  
 Produce more evidence about cost-effectiveness of pharmacogenomics tests in real 
world settings.  
 Develop information systems to improve integration of genomic data with patient health 
record data and to provide advanced decision support for clinicians 
 Develop and adopt standard data exchange interfaces to enable interoperability 
between sources of data, information systems, health care institutions, and centralised 
electronic health records and databases.  
 Build capabilities and secure protocols to store genomic data which can be reused. As 
a person’s genome remains unchangeable over time genomic data can be reused. This 
will bring down unit cost making it cost-effective to utilise it for various purposes. 
However, protocols are required to ensure personal data protection and maintain 
patients’ confidence on privacy. The national Genome Centre is planned to provide this 
kind of centralised capability.  
 Develop and adopt platform-based analytics solutions which automate data storage, 
integration, and analytics.  
 Support to experiments and pilots. There are many funding alternatives to financing 
pilots: R&D grant funding, challenge-based contests, or public procurements of demo 
solutions.  
 
8.4 Direct-to-consumer genomics  
Consumer genetic testing services have been available for some time already. The first 
services were targeted at studying person’s ancestry and soon followed by health-related tests. 
Recently introduced consumer services now extend beyond medical health domain into 
wellbeing, nutrition and sports. An example is a test provided to assess optimal sports 
rehearsal and nutritional program based on a person’s genetic type.  
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Demand. Marketing and sales of genetic testing services are not simply responding to pre-
existing demand on the market, but also actively aiming to create demand and establish a 
market (Udesky 2010). The market of direct-to-consumer genetic tests is estimated worth 70 
million US dollars in 2015 and expected to grow five-fold by 2022.  
The proliferation of direct to consumer genetic services has led to increased demand for 
genetic counselling services. Their use is recommended by clinical professionals to improve 
interpretation of results and avoid unnecessary anxiety. The US labour authorities have 
estimated that the genetic counselling field is expected to grow by 29 percent through 2024. It 
is also becoming more professionalised with accreditation mechanisms being developed. In 
Finland, an example of a genetic counselling service is provided by DiagFactor to assess 
genetic risks for obesity, heart illnesses, and nutritional guidance. The service also covers 
interpretation of the results. The marketing claim for the service is promotion of proactive 
healthcare. Another company active in the field is Negen.  
Supply. A review published in 2016 found 136 companies that offer consumer genetic testing 
covering a large variety of tests including paternity tests and child talent tests (Phillips 2016). 
The typical operating model is provision of genetic tests directly to consumers, mainly via the 
internet subscription and delivery. The service usually includes provision of a sample kit, return 
of the sample via post to the service provider, and reception of the results via email or online 
web portal. Some of the most well known companies providing direct-to-consumer genetic 
testing services are 23andMe, FamilyTreeDNA, Ancestry.com, and MyHeritage. Services from 
these companies have been available a little over a decade (since 2007).  
In the United States, the Food and Drug Administration (FDA) has approved the first genetic 
health risk tests to be marketed directly to consumers in 2017. The approved tests cover ten 
diseases or conditions including Parkinson’s disease, late-onset Alzheimer’s disease and 
hereditary thrombolia. In their approval letter the FDA emphasizes that while the tests may 
provide genetic risk information to consumers, the tests cannot determine a person’s overall 
risk of developing a disease or condition. There are also many other factors that contribute to 
the development of a health condition, including environmental and lifestyle factors.  
Perkin Elmer has recently introduced genetic tests for 59 genes which have been confirmed 
to play a role in one of 34 health conditions, to all of which there are treatments available. The 
tests are primarily targeted at healthy individuals. The company will be selling the tests through 
Helix, a consumer marketplace, bringing together a variety of genetic tests for health and other 
purposes.  
The business model of Helix is based on a platform strategy connecting users and genetic test 
providers on a single marketplace. For 80 US dollars fee, Helix will sequence the full exome 
(the portion of the genome responsible for coding proteins) and additionally some noncoding 
regions of the genome. Helix stores the information in digital form. The customer can then 
authorize any of Helix’s multiple service providers to provide genetic tests. Whereas the first 
genetic test companies entering the consumer market (e.g. 23andMe) use more limited 
genotyping technology Helix uses DNA sequencing which yields about 100 times more 
information. Helix also collects and sequences a DNA sample only once and stores it so that 
the customer can access additional DNA analysis products without providing another saliva 
sample. Helix online test shop covers services from health and diet to ancestry, family 
planning, fitness and even entertainment applications (e.g. wine recommendations based on 
client’s genotype).  
Drivers. An essential driver of consumer demand for genetic tests is personal concern about 
risk for genetically-dependent diseases and health conditions. It has been argued that there is 
a trend towards decentralization, consumerization and democratization of care delivery 
models. Access to information over the internet leads to increased awareness and active 
engagement of people over their health. Another powerful trend impacting consumer behaviour 
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is increasing desire to measure physical characteristics and underlying factors. The so called 
’quantified self’ movement is an extreme manifestation of this kind of thinking.  
The main technological driver is decreasing cost of testing which has rapidly brought also more 
extensive whole genome sequencing services to a reasonable price category for larger groups 
of consumers. Combined with business models where the full cots of testing is not charged 
from the consumer, but covered by the service provider in return for future revenue for 
additional sales makes it possible to offer very attractive prices for consumers.  
Barriers. The regulatory environment for testing companies has been uncertain during the first 
decade of their operation. There has been inclarity about how genetic tests for consumers are 
to be classified and whether they need to comply with regulations for medical devices. The 
market has taken off initially in the United States where regulation has been rather permissive. 
In Europe each country has their own regulatory framework in place. Finland has ratified the 
European Convention on Human Rights and Biomedicine which also regulates use of genetic 
testing. The agreement specifically prohibits any discrimination against a person on the 
grounds of genetic heritage and performance of predictive tests for genetic diseases for other 
reasons than health purposes. It also excludes the modification of the human genome for other 
than preventive, diagnostic or therapeutic purposes. However, the current legal interpretation 
of the agreement’s application does not cover services provided on the consumer market but 
only actions performed by healthcare providers and public authorities. In the draft proposal for 
Genomic Law, genetic tests sold on the consumer market are proposed to fall under consumer 
legislation and general data protection regulation (GDPR).  
It has been argued that since the majority of companies do not currently offer whole-genome 
or whole-exome scans it means that the utility of test results for the persons tested is inherently 
rather limited (Phillips 2016). Another criticism is that risk predictions might have no clinical 
relevance, and might give false alarms or false assurance (Udesky 2010). Results might be 
also difficult to interpret and should be done together with qualified professionals. Also, 
concerns have been raised about the quality of some of these tests (Udesky 2010, Tandy-
Connor 2018). There has been controversy about the accuracy of the tests as well as how to 
interpret results correctly (Phillips 2016). A recent validation study found that 40 % of consumer 
genetic tests gave false positives related to raw genotyping data (Tandy-Connor 2018).  
Also data security and personal identity are issues which are seen as potential risks slowing 
down their widespread use (Phillips 2016). There is a lack of common security standards for 
ethical concerns and privacy. Potential risks of compromising the privacy protection include 
loss of donor anonymity and data leaks (Ayday et al. 2015). Also the fact that a person’s 
genotype is shared among close relatives creates an ethical issue that also family members 
could be identified from the genetic profile data.  
A barrier to wellbeing applications is the fact that genetic data alone is not likely to be valuable, 
but combined with other personal data it is likely to provide one important input to various 
counselling services. Further product and technology development will be needed to improve 
capabilities to integrate various types of health data from different sources to enable tailor-
made and personalised analyses.  
Business models. Early genetic tests to consumers have been based on a simple fee for 
service revenue model. Recently more complex business models are emerging. Some may 
offer subsidized test prices in return for the right to use personal genomic data. Others 
experiment with solutions enhancing data security and privacy with new technology such as 
blockchains. An interesting business model is the platform model where consumers and 
genetic test providers are linked together on a marketplace. The genetic data submitted by 
consumers is analyzed and stored by the platform company. The consumer may then authorize 
any of the service providers to get the data and perform tests ordered by the consumer.  
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As direct-to-consumer genetic test services are provided mostly online and traded overseas 
there is an emerging need for genetic counselling to ensure correct interpretation of findings. 
Some of the firms provide counselling with a fixed staff, others connect a large pool of experts 
on a part time basis. Professionalisation of genetic counselling is expected. Also some forms 
of ’gig’ economy business models among medical experts might appear in this space.   
 
Policies and strategies 
 Establish and apply quality standards for direct-to-consumer tests in a way which easily 
communicates the reliability and relevance of a test to the consumer. This might also 
involve more clear distinction between scientifically qualified health tests from other 
tests with primarily entertainment or lifestyle function.  
 Provision of interpretation services of genetic test results by qualified healthcare 
professionals having skills to assess the results in the context of several other factors 
such as personal and family medical history. 
 Taking advantage of the emergence of platform-based business models for genetic 
testing; either as a platform owner, or service supplier operating on the platform 
enabling fast scalability opportunities.  
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9 Ecosystem model 
9.1 System dynamic modelling  
In order to examine alternative development paths of a data-driven precision medicine 
ecosystem, a system dynamics model was developed. System dynamic modelling is an 
approach to study the behaviour of complex socio-technical systems. In the approach, the 
structure of the system (i.e. chains of cause and effect and feedback loops) are first 
conceptualized. Then, the behaviour over time of the system is examined using computer 
simulation.  
Systems described by system dynamics models are typically large, complex, nonlinear sets of 
differential equations. Theoretical system analysis usually fails in these cases, mainly because 
linear approximations cannot be used. Top-line structural analysis can be performed (such as 
analysis of dominating positive and negative feedback loops and their interactions) but 
theoretical analysis is beyond the grasp of the modeller.  
This lack of theoretical analysis tools leaves the theoretical modeller somewhat running on 
empty; the main methods left are simulation and experimental analysis of data. Nevertheless, 
the theoretical analysis of structure gives important insight to the potential behavioural patterns 
of the system, may they be desired or unwanted (e.g., exponential growth, death spiral, rise 
and collapse, oscillation, balancing buffer and inertia, to name but a few). Structural analysis 
is a tool for evaluating different behavioural modes and alternative futures. Computer 
simulations give more insight to dominance of behavioural patterns, leverage variables and 
quantitative metrics (Ylén and Hölttä 2007) 
 
 
Figure 3. What are system dynamic models used for 
 
9.2 Model of precision medicine ecosystem 
In the emerging data-driven precision medicine ecosystem, the main stock variables that 
change through time are the amount and quality of data, the level of research and 
entrepreneurial activity, and the size of the market based on data-driven precision medicine. 
These stock variables are key factors for developing a new innovation and business ecosystem 
for precision medicine.  They determine the critical mass for breakthrough in different future 
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scenarios and their interdepencies create drastically different dynamics. For instance, the 
amount of data determines the value and usefulness of the database, the level of 
entrepreneurial activity is the seed for a Finnish precision medicine ecosystem and the size of 
market correlates to the profit potential in different business models. The limits of usable data 
and business activity came up in the interviews. 
The causalities of ecosystem factors are described in feedback loops, which are shown in 
Figure 4. 
 
 
Figure 4. Stock-flow system dynamics model 
The model includes the following reinforcing feedbacks related to the growth of an ecosystem 
based on health data: 
 R1: Entrepreneurial and research activities: New research and business activities 
depend on the availability of consolidated data. An increase in the amount of data can 
result in an increase in research and business activities. In the model, it is assumed 
that an increase in research and entrepreneurial activities makes the ecosystem 
increasingly attractive for other companies, thus increasing the level of research and 
entrepreneurial activities in the ecosystem further. 
 R2: Market creation: The creation of a new market (i.e. the emergence of new B2C 
services based on health data) is dependent on the existing entrepreneurial activities 
in the ecosystem. Once a market for the new services exists, firms can invest profits 
from sales further. This increases the level of research and entrepreneurial activities 
in the ecosystem leading to further growth of the market. 
 R3: Data generation: Once a market has emerged, it is possible to collect more data 
from end users in the market. This can then boost new research and business activities 
and the growth of the market further. 
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Various stakeholders are prominent in different parts of the ecosystem model:  
 Data-owners boosting or hindering the creation and use of data. 
 Research service providers are the enablers in research activity. 
 Start-ups and established companies provide the entrepreneurial activity. 
 Data-users determine the market size. 
 
9.3 Simulation results 
A first question addressed using the simulation model is how to speed up the identified 
reinforcing feedback loops related to investments in business activities, market creation, and 
the generation of data. 
In the model, resources can either be used for acquiring new health data or supporting new 
businesses in the emerging ecosystem. In the simulation experiments, the effects of different 
levels of resource allocation are compared. As shown by the results, either a too low (0.1) or 
too high (0.9) fraction of resources that are invested into data acquisition can slow down the 
growth of the ecosystem. This means that by boosting dominantly either data acquisition or 
entrepreneurial activity only affects one part of the ecosystem and the neglected part left for 
evolutive natural selection develops significantly slower hindering the overall development of 
the ecosystem. 
In addition, in the figure below the dotted lines show how the results change if external support 
of the ecosystem ends at year 15. In the long term, it is essential that the ecosystem is not 
dependent on external support (external resources in Figure 4). These regulatory and incentive 
based support systems are described in detail in policies and strategies of Chapter 8. 
 
Figure 5. Effect of resource allocation to data acquisition and supporting business activities 
In the next simulation experiment, we consider a situation in which there are two competing 
ecosystems based on health data. We assume that in ecosystem 1, data acquisition is faster, 
which can reflect a difference in legislation related to data collection. However, in ecosystem 
2 there are more efficient mechanisms for market creation for the use of health data as well as 
more research service providers. These differences are reflected in different values of the 
parameters 'Effect of external factors on data acquisition' (impact on data acquisition rate in 
model) , 'Effect of entrepreneurial activity on market growth' (impact on market growth rate in 
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model), and 'Research service providers' (impact on new research and business activities rate 
on model). 
 Ecosystem1 Ecosystem2 
Effect of external factors on data acquisition 0.05 0.03 
Effect of entrepreneurial activity on market growth 1 1.5 
Research service providers (between 0 and 1) 0.9 1 
 
Ecosystem 1 describes a situation in which data acquisition is boosted by, e.g., legislation and 
financial benefits but the start-ups and businesses are left on their own whereas in ecosystem 
2 data acquisition is driven by market and business forces and the entrepreneurial research 
activity is dominating factor. Ecosystem 2 corresponds to the consumer driven business 
scenario described in chapter 8.4. 
As indicated by the simulation results, the relative benefit of faster data acquisition results in a 
faster growth in research and entrepreneurial activity of ecosystem 1 during the initial phases 
of ecosystem development. However, in the longer term the efficient creation of a market is 
necessary for sustained growth. This is why in the longer term the research and entrepreneurial 
activity of ecosystem 2 is higher. 
 
Figure 6. Competition of two rival ecosystems 
 
A third question addressed is how the ecosystem development and value creation is affected 
by multiple data sources beyond health data. As indicated by the simulation results, reducing 
the resources allocated to health data and allocating them to non-health data acquisition and 
business support can increase the growth of the ecosystem that is based on health data. The 
reason is that due to the reinforcing feedback R3, an emerging market for non-health data can 
also help increase the health data that is collected. This case also corresponds closely to 
chapter 8.4. 
One example of this is leisure and sport data.  All this personal data can be used for precision 
medicine and by fusing the data and as for instance genetic data is collected for sport it can 
also be collected for medical use. 
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Figure 7. Effect of non-health data on ecosystem growth 
The system dynamics model developed was used to study how the development of a data-
driven precision medicine ecosystem depends on different factors. Specifically, factors 
affecting the rate of data acquisition, new business and research activities, as well as the 
growth of a new market were examined. The presented results are initial examples showing 
how system dynamics models can be used for ecosystem simulation. In future work, the model 
will be validated and improved based on available data sources. In addition, the model will be 
used for simulating the effects of alternative policies that aim at accelerating the emergence of 
the data-driven precision medicine ecosystem.  
A more detailed system dynamic model can be created for the patient care level. The model 
can be used for evaluating effects of more precise diagnosis, tailored treatment solutions, 
screening procedures, etc. to patient care paths, outcomes, costs, quality of life to name but a 
few.  
 
 
 
 
 
 
 
              59 (75) 
 
 
 
10 Conclusions 
This report provides an overview of the Finnish infrastructure, stakeholders and business 
potential in the field of data-driven precision medicine. In particular, the report focuses on 
opportunities opened by secondary use of health related data as enabled by biobanks and 
other data sources. The observations are based on openly available information and interviews 
of key stakeholders, including representatives of both companies and public sector 
organisations.   
There are several on-going public sector activities targeted at supporting data-driven precision 
medicine. These include new legislation (e.g. the Secondary Use Act, new Biobank Act and 
Genome Act), centralized data storages (Kanta services, genome database), services 
supporting data access (Service Operator, Finnish Biobank co-operative) and collaborative 
research activity, most notably the FinnGen project. Overall, the Finnish infrastructure  is well-
developed, internationally competent, and the on-going development activities are widely 
appreciated. At the same time, there are worries concerning the delayed time schedules of the 
public activities in setting up the infrastructure. It is also still unclear for the stakeholders, what 
kind of data and under which conditions will be available for secondary use. Additional 
guidance for interpreting the legislation will be needed.  
The review of international developments in precision medicine revealed a large number of on-
going efforts targeted at collecting genome data via sequencing projects, supporting co-
operation between stakeholders and improving access to data resources and processing tools. 
Also a large amount of genome and other omics data is openly available from several sources. 
However, open access was observed to normally apply only to molecular level data: access to 
more useful data resources, which combine omics and phenotype data is restricted to scientific 
research. Such restrictions could be avoided in the future by portals, which enable individuals 
to donate their data for open use, although clear evidence of the feasibility of this model is still 
missing.  
Although the market potential of precision medicine is high, most Finnish SME's in the domain 
are still unprofitable although some of them show growth in turnover.  Many SME's have 
difficulties in initiating co-operation with larger organisations and, in general, the companies 
felt that public healthcare service providers should be more active in testing and adopting new 
technologies and innovations introduced by the industry. Apart from a few exceptions, most 
SME's also could not see direct benefits from the FinnGen for themselves, although the 
project's high value for pharma industry, academic research and for the visibility of Finland was 
largely recognized. The pharma sector has a long tradition of exploiting health data e.g. in Real 
World Evidence (RWE) studies and, therefore, were more positive about getting benefits from 
biobanks and the Service Operator. It seems evident that the SME's currently providing 
research services for pharma companies could enlarge their service offerings towards 
companies in other sectors. The interviews revealed that there is a high potential for exploiting 
health data in sectors such as healthcare services, medical device manufacturing and food 
industry, but support from experienced research service partners is needed.  
Better availability of health data for secondary use opens up opportunities to Artificial 
Intelligence based applications. We have identified several potential use cases for AI 
technology. AI can speedup the data dependent processes and enable professionals to make 
more accurate decisions faster. It can be used also to find bottlenecks of the processes and to 
find solutions for solving the problems. 
Based on the interviews, it is clear that companies are still in the early phase of developing 
precision medicine based business. In order to accelerate this process, we have analysed 
business opportunities in four areas covering new therapy development, health risk 
assessment and diagnostics, therapy selection and direct-to-consumer genomics. The 
analysis included estimation of the demand and supply factors in each opportunity area as well 
as identification of the related drivers and barriers. The analysis resulted in policies and 
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strategies, which should be adopted to remove the main barriers. Many of the companies 
would benefit from actions that would accelerate adoption of new precision medicine solutions 
by users, create preconditions for market shaping and consolidation, and support scaling-up. 
Various potential actions were identified, such as more systematic practices for undertaking 
pilots and experiments with healthcare organisations, developing clinical guidelines, improving 
interoperability and integration capabilities, and generating evidence about cost-effectiveness 
of precision medicine solutions.  
The observations of this study enforce our preconception that successful business in data-
driven precision medicine relies on networked stakeholders. In order to understand the 
mechanisms of the business ecosystem an initial ecosystem model was constructed. The 
model enables the simulation of different alternative development paths for the data-driven 
precision medicine ecosystem. Initial simulation results reveal the importance of balanced 
investment  for increasing the amount of available data and for new business and market 
creation.  The early results show how system dynamics models can be used for such 
ecosystem simulations.  
This report provides a basis for further work planned to be carried out in the PreMed project 
during September 2018 - April 2020. The further activities are planned to include a research 
study targeted at collecting evidence on the benefits on applying precision medicine, e.g.  
pharmacogenomics tests, in healthcare. In addition to the scientific objectives the study is 
expected to provide information about the functionality of data access processes of biobanks 
and the Service Operator and to pinpoint related bottlenecks. Additionally, the ecosystem 
simulation model will be validated and improved based on available data sources and new 
models will be added for simulating the impact of precision medicine applications in specific 
patient care paths. The project will collaborate closely with the FinnGen project as well as 
related projects to be started in the framework of the Personalized Health and Artificial 
Intelligence programs of Business Finland.   
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Terms and acronyms 
 
Term / acronym Description 
AI Artificial Intelligence 
anonymous data Anonymous data are defined as information which does 
not relate to an identified or identifiable natural person 
or to personal data rendered anonymous in such a 
manner that the data subject is not or no longer 
identifiable (Chassang 2017). 
B2B  business-to-business 
B2C business-to-consumer 
BBMRI Biobanking and BioMolecular resources Research and 
Infrastructure 
biobank Biobanks are collections of biological samples and data 
gathered with the donor’s consent for future medical 
research and product development for healthcare and 
health promotion purposes1. 
CDSS Clinical Decision Support System 
CNN Convolutional Neural Network 
DL Deep Learning 
DNN Deep Neural Network 
DSS Decision Support System 
EHR Electronic Health Record 
FDA Food and Drug Administration 
Fimea Finnish Medicines Agency 
FINBB Finnish Biobank co-operative 
FIOH Finnish Institute of Occupational Health 
GDPR General Data Protection Regulation  
HUS The Hospital District of Helsinki and Uusimaa 
ICT Information and Communications Technology 
Isaacus Project initiated by Sitra with the objective of setting up 
an organisation to take responsibility of providing 
access for secondary use of health and wellness data 
in Finland2.  
Kela The Social Insurance Institution of Finland 
LSTM Long Short Term Memory 
NLP Natural Language Processing 
NN  Neural Network 
                                               
1 https://www.biopankki.fi/en/ 
2 https://www.sitra.fi/artikkelit/isaacus-national-health-data-hub/ 
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omics Refers to a field of study in biology ending in -omics, 
such as genomics, proteomics or metabolomics. Omics 
aims at the collective characterization and quantification 
of pools of biological molecules that translate into the 
structure, function, and dynamics of an organism or 
organisms1. 
PHR Personal Health Record 
PM Precision Medicine 
pseudonymisation Pseudonymisation means the processing of personal 
data in such a manner that the personal data can no 
longer be attributed to a specific data subject without 
the use of additional information, provided that such 
additional information is kept separately and is subject 
to technical and organisational measures to ensure that 
the personal data are not attributed to an identified or 
identifiable natural person. Pseudonymised data 
remains personal data but being protected through 
coding or encryption (Chassang 2017). 
secondary use Secondary use of health and social care data relates to 
information collected in the course of providing 
healthcare or social services, but being used for 
purposes other than the patient care, i.e. research and 
development.2 
Secondary Use Act Refers to the national legislation on secondary use of 
health and social data (currently in acceptance process 
of the Parliament of Finland).   
Service Operator National operator for providing access to data for 
secondary use as enabled by the Secondary Use Act 
(currently in set-up phase).  
Sitra The Finnish Innovation Fund 
STM Ministry of Social Affairs and Health 
THL National Institute for Health and Welfare  
Valvira National Supervisory Authority for Welfare and Health 
VRK Population Register Centre 
VSSHP Hospital District of Southwest Finland 
 
 
 
 
                                               
1 https://en.wikipedia.org/wiki/Omics 
2 Deloitte: International review on the secondary use of health and social care data and applicable 
legislation 
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Appendix 1. Precision medicine initiatives 
Country Project Budget Sequencing 
goals 
Aims and objectives 
African 
continent 
Human Heredity and 
Health in Africa 
(H3Africa)1 
 
2010– ongoing 
~32 M€ 
(2011-
2016) 
N/A  To create a pan-continental network 
of laboratories 
 Ensuring access to relevant 
technology 
 Clinical integration 
 Facilitating training 
China China Precision 
Medicine Initiative2  
 
2016-2030 
~8000 M€ 2000 individuals 
(initial), aims at 
100M in 2030 
 To fund national precision medicine 
projects 
Denmark National strategy for 
personalised 
medicine 3 
 
(2017-2020) 
~13 M€ 
(initial 
invest.) 
N/A  Establish a foundation for the 
development of better and more 
targeted health care for patients, 
through the use of new technologies 
and new knowledge 
 Strengthen the ethical, legal and 
safety aspects related to the use of 
genetic in-formation in health care 
 Establish a joint governance structure 
and strengthen collaborations across 
the country – both in healthcare and 
research 
 Establish a cooperation about a safe, 
joint and coherent technological 
infrastructure 
 Initiate relevant research – and 
development projects 
Estonia Estonian Biobank 
EGCUT4 
 
(2000-ongoing) 
5 M€  
(in 2018) 
100 000 in 2018, 
already contains 
52 000  
 International ambition to be a leading 
genome center in Europe  
 Advancing science, conducting 
research and education 
 Gather population health data and 
hereditary information to improve 
public health 
 Be the main force in the development 
of personalised medicine in Estonia 
                                               
1 https://h3africa.org/ 
2 https://www.weforum.org/agenda/2017/11/3-ways-china-is-leading-the-way-in-precision-medicine/   
3 http://www.sum.dk/English/Healthcare-in-Denmark-An-Overview/Personalised-Medicine.aspx 
4 https://www.geenivaramu.ee/en  
https://www.genomeweb.com/genetic-research/estonia-invests-5m-genotype-100k-people-2018-part-
personalized-medicine-project  
https://www.geenivaramu.ee/en/about-us/egcut-development-plan-2015-2021 
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Country Project Budget Sequencing 
goals 
Aims and objectives 
Finland Finland’s genome 
strategy 
implementation1 
 
(2015-ongoing) 
N/A N/A  Make Finnish healthcare more 
effective through making genomic 
data more widely used for and 
interconnected between individuals, 
healthcare and research.  
 Transform Finland into an attractive 
environment for research and 
business in genomics 
Finland FinnGen
2 
 
(2017-2023) 
59 M€ 500 000 
individuals by 
using samples 
from national 
biobanks 
 Produce medical innovations 
 Support Finland to become a pioneer 
in biomedicine and personalised 
healthcare. 
 Create a co-operation model between 
public sector and healthcare industry. 
 Provide early access to new 
personalised treatments and health 
innovations for all Finns. 
France The French Plan for 
Genomic Medicine 
20253 
 
(2016-2025) 
670 M€ 235 000 patients 
annually by 
2020 
 Position France as a leading country 
in PM 
 PM integration into the clinical 
pathway and management of 
common diseases 
 Create a national genomic medicine 
framework that facilitates innovation, 
capitalization and economic growth 
Japan Japan Initiative on 
Rare and 
Undiagnosed 
Diseases (IRUD)4 
 
(2014-2018) 
~10 M€ 
(2014) 
 N/A  To create a comprehensive medical 
network and an internationally 
compatible data-sharing framework 
 
Netherlands Hartwig Medical 
Foundation5  
(2015-ongoing) 
N/A Whole genome 
sequencing data 
40 per week, 
currently 2700 
 To enable personalized treatment for 
cancer patients 
 Set up a databank to increase 
diagnosis and treatment quality, 
reduce costs of care and support 
clinical integration 
                                               
1 https://media.sitra.fi/2017/02/28142539/Improving_health_trough_the_use_of_genomic_data.pdf 
2 https://www.finngen.fi/en 
3 http://solidarites-sante.gouv.fr/IMG/pdf/genomic_medicine_france_2025.pdf 
4 https://www.amed.go.jp/en/program/IRUD/ 
https://www.nature.com/articles/ejhg2017106 
 https://www.ncbi.nlm.nih.gov/pubmed/28794428 
5 https://www.hartwigmedicalfoundation.nl/en/ 
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Country Project Budget Sequencing 
goals 
Aims and objectives 
New 
Zealand 
Precision Driven 
Health Initiative1 
 
(2016-ongoing) 
~22 M€ 
(7year 
investment
) 
N/A  Accelerate research 
 Utilize various data sources, incl. big 
data 
 Support self-management 
technologies 
South Korea The South Korean 
Cohort Study2  
 
(2017-ongoing) 
~48 M€ 10 000 Cancer 
patients 
 To develop targeted therapies for 
cancer patients 
 Developing a cloud-based hospital 
information system  
Sweden Genomic Medicine 
Sweden (GMS)3  
(2017-2023) 
 
~390 k€ 
(pre 
analysis 
phase) 
25 000 genomes 
annually 
 To build an infrastructure to facilitate 
PM integration into the Swedish 
healthcare system 
Switzerland Swiss Personalized 
Health Network 
(SPHN)4  
(2017-2020) 
~60 M€ 
(2017-
2020) 
N/A 
 
 Accelerate development of PM 
 Facilitates research projects, data 
sharing and infrastructure projects 
UK Genomics England
5,6  
 
(2013-ongoing) 
~515 M€  100 000 whole 
genomes from 
~70 000 
individuals 
 Implements the 100 000 Genomes 
Project 
 Create a new medicine service for 
NHS 
 Accelerate medical research 
UK The Scottish 
Genomes 
Partnership7  
 
(2015-ongoing)  
~17 M€ 
(initial 
investment 
in 2015) 
1377 genomes 
sequenced in 
May 2018 
 The partnership leads four research 
areas: cancer, genetic diseases, a 
Scottish population study, and it 
collaborates with Genomics England  
USA Precision medicine 
initiative and All of Us 
Research Program8 
 
(2015-ongoing)  
~1252 M€ 
(2018-
2028) 
1 million 
volunteers 
 To build a national research 
participant group  
 To develop precision medicine in 
oncology  
 To start the research project called 
All of Us. 
                                               
1 http://www.precisiondrivenhealth.com/ 
2 http://www.koreabiomed.com/news/articleView.html?idxno=1267 
3 http://swelife.se/vi-erbjuder/fornyelse/gms-genomic-medicine-sweden/ 
https://ki.se/en/mmk/new-national-initiative-for-precision-medicine-genomic-medicine-sweden 
https://www.equalis.se/media/127583/lucia-cavelier_genomics-medicine-sweden.pdf 
4 https://www.sphn.ch/en.html 
5 https://www.genomicsengland.co.uk/ 
6 https://cnfl.extge.co.uk/display/SDKB/100%2C000+Genomes+Project+-
+Frequently+Asked+Questions 
7 https://www.scottishgenomespartnership.org/ 
8 https://ghr.nlm.nih.gov/primer/precisionmedicine/initiative 
https://allofus.nih.gov/ 
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Country Project Budget Sequencing 
goals 
Aims and objectives 
USA Million Veteran 
Program1 
 
(2009-ongoing) 
N/A Currently 
~600 000 (aims 
at 1 million) 
 Investigate how genes affect health 
 Build worlds largest database with 
blood samples and health information 
 
 
                                               
1 https://www.research.va.gov/mvp/ 
https://www.sciencedirect.com/science/article/pii/S0895435615004448 
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Appendix 2. Non-profit precision medicine organisations  
 
Country Project Aims and objectives 
Europe International Consortium 
for Personalised Medicine 
(ICPerMed) 
(2016)1 
 Facilitates collaboration in personalized medicine research, 
implementation and funding. 
 Accelerate research by coordinated approaches 
 Support research into benefits of personalized medicine with 
emphasis on healthcare systems and citizens.  
 Support PM approaches for citizens 
Europe European Personalised 
Medicine Association 
(2009)2 
 Promotes adoption of and access to personalized medicine, 
promotes advanced diagnostics 
 
Europe European Alliance for 
Personalised Medicine 
(2012-ongoing)3 
 Promotes development,  adoption of and access to 
personalized medicine, promotes diagnostics 
 
USA The Personalized Medicine 
Coalition (PMC)4 
 
(2005) 
 PM advocacy group; raising awareness, education for 
healthcare workforce, policymakers. 
 Influencing regulatory frameworks, public policies to invest in 
PM products  
Global Global Alliance for 
Genomics and Health5 
(2013) 
 Non-profit alliance working to create frameworks and 
standards for responsible, voluntary and secure sharing of 
genomic and health related data 
Global Global Genomic Medicine 
Collaborative6 
(2016) 
 Create networks and collaborations  
 Provide a knowledge base for best practices and genomic 
medicine activities 
 Assist in clinical implementation and evidence generation 
                                               
1 https://www.icpermed.eu/ 
2 http://www.epemed.org 
3 https://www.euapm.eu/ 
4 www.personalizedmedicinecoalition.org 
5 https://www.ga4gh.org/ 
6 https://g2mc.org/ 
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Appendix 3. Data access, information sharing and collaboration 
structures 
 
Organisation Content Data 
AHA Precision 
medicine platform1 
(USA) 
Cloud-based data resource for cardiovascular 
diseases. Provides open access to 
cardiovascular data sets, tools and forums for 
collaboration. 
Clinical health data, lifestyle data, 
genetic data, cardiovascular and 
stroke data. 
Canadian Open 
Genetics Repository 
(COGR)2 
Collaborative effort for the collection, storage, 
sharing and robust analysis of variants reported 
by medical diagnostics laboratories across 
Canada.  
Information related to human gene 
DNA variants and their relationship to 
disease. 
ELIXIR3 (Europe) Provides infrastructure to enable public sharing 
of genetic data, services for permanent archiving 
and distribution of personally identifiable genetic 
and phenotypic data.  
Genetic and phenotypic data. 
European Bio 
Informatics institute 
(EMBL-EBI)4 
Shares data (e.g. nucleotide sequences) and 
tools originating from life science experiments.  
Biological data sources covering: 
DNA&RNA, Gene Expressions, 
Proteins, Structures, systems, 
chemical biology, and ontologies. 
European Genome-
phenome Archive 
(EGA)5 
An EMBL-EBI service for permanent archiving 
and distribution of personally identifiable genetic 
and phenotypic data resulting from biomedical 
research projects. 
Personally identifiable genetic and 
phenotypic data. 
Global Alliance for 
Genomics and Health 
(GA4GH)6 
Non-profit alliance that works to create 
frameworks and standards to enable sharing of 
genomic and health related data. Develops 
standards, tools, and frameworks that are 
designed to overcome technical and regulatory 
hurdles to international genomic data sharing. 
- 
International Cancer 
Genome Consortium 
(ICGC)7 
Coordinates a large amount of research projects 
globally to generate comprehensive catalogues 
of genomic abnormalities. Provides tools for 
visualizing, querying and downloading the data 
released quarterly by the consortium's member 
projects. 
Cancer genomes at the genomic, 
epigenetic and transcriptomic levels. 
PrecisionFDA8 (USA) PrecisionFDA is a research sandbox that 
provides the genomics community with a web 
portal where they can experiment, share data 
and tools, collaborate, and define standards for 
evaluating analytical pipelines.  
- 
                                               
1 https://precision.heart.org/ 
2 http://opengenetics.ca/ 
3 https://www.elixir-europe.org/ 
4 https://www.ebi.ac.uk/ 
5 https://www.ebi.ac.uk/ega/home 
6 https://www.ga4gh.org/ 
7 http://icgc.org/ 
8 https://precision.fda.gov/ 
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Organisation Content Data 
The National Cancer 
Institute (NCI) Genomic 
Data Commons (GDC)1  
The NCI's Genomic Data Commons (GDC) 
provides the cancer research community with a 
unified data repository that enables data sharing 
across cancer genomic studies in support of 
precision medicine.  
Cancer genomic data including 
mutations, copy number variants, 
mRNA and miRNA sequence data, 
post-transcriptional modifications. 
The National Genomics 
Infrastructure (NGI) 2 
(Sweden) 
Provides access to technology for massively 
parallel/next generation DNA sequencing, 
genotyping at all scales and associated 
bioinformatics support to researchers based in 
Sweden.  
- 
The Personal Genome 
Project3 (International) 
A coalition of projects across the world 
dedicated to creating public genome, health, and 
trait data.  
Genome, health, and trait data. 
 
 
                                               
1 https://gdc.cancer.gov/ 
2 https://ngisweden.scilifelab.se/about 
3 https://www.personalgenomes.org/ 
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Appendix 4. Data access guidance comparison 
 
Organisation Content Guidance for data access  
Auria Biobank1 Provides biological samples  collected in connection 
with normal health-care and medical examinations for 
use in medical research. 
Instructions and forms available for 
applying data. 
Helsinki Biobank2 Helsinki Biobank provides samples with associated 
clinical information, for medical research and R&D 
purposes. 
Instructions available for applying 
data (forms for availability requests). 
Turku Clinical 
Research Centre3 
Clinical informatics service responsible for 
maintaining the hospital district’s patient information 
and making it available for research purposes.  
Instructions for access published.  
THL Biobank4 THL Biobank hosts a remarkable collection of 
population and disease-specific samples for research 
purposes. 
Instructions and prices available for 
applying data. 
China Kadoorie 
Biobank5 
Population based biobank with questionnaire data 
and physical measurements, blood samples and 
health outcome data. 
Instructions and criteria for access 
published. 
UK Biobank6 Collection of questionnaire data, blood, urine and 
saliva samples and healthcare follow-up data of 500 
000 individuals. Includes EHR, lifestyle, health and 
genotype data. 
Instructions and costs for access 
published. 
Norway HUNT7 Questionnaire data and biological specimens from the 
general population. 
Instructions and costs for access 
published. Norwegian research 
partner required. 
Norwegian 
Institute of  
Public Health8 
Joint service for accessing data from health registries 
and health studies as well as samples from 
Norwegian biobanks.    
Instructions and costs for access 
published.  
Cancer registry of 
Norway /  
Janus Serum 
Bank 
Population based biobank for cancer research. Instructions for access published. 
Norwegian research partner required. 
Danish National 
Biobank 
National biobank with large sample collection and 
information about samples elsewhere in the Danish 
health system. 
Instructions for access published. 
Danish research partner needed. 
Biobank Sweden Centralized service point for Swedish biobanks. Instructions and forms available for 
applying data (application shall be 
directed to the specific biobank 
owning the sample/data). 
                                               
1 https://www.auriabiopankki.fi 
2 https://www.terveyskyla.fi/helsinginbiopankki/en 
3 http://www.turkucrc.fi/en 
4 https://thl.fi/en/web/thl-biobank/for-researchers 
5 http://www.ckbiobank.org/site/ 
6 http://www.ukbiobank.ac.uk/ 
7 https://www.ntnu.edu/hunt/data 
8 https://www.fhi.no/en/ 
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Organisation Content Guidance for data access  
LifeGene 
Sweden1 
Prospective cohort study including periodically 
collected questionnaire data, physical measurements 
and samples. Also includes health registry data. 
Instructions and costs for access 
published. Association with Swedish 
university or research institute 
required. 
The Estonian 
Biobank 
(University of 
Tartu)2 
Population based biobank including a cohort of > 
50 000 people. Collects i.e. health, lifestyle, 
demographic, and genetic data. 
Instructions for access published. 
Hatwig Medical 
foundation  
(Netherlands)3 
A database of biopsy samples and clinical parameters 
of patients recruited for studies of the Center for 
Personalized Cancer Treatment (CPCT). Collects 
genetic and clinical data from cancer patients. 
Instructions for access published. 
Biobank Graz4 Comprises both population-based and disease-
focused collections of human biological material. 
Instructions and forms available for 
applying data. 
 
                                               
1 https://www.lifegene.se/ 
2 https://www.geenivaramu.ee/en 
3 https://www.hartwigmedicalfoundation.nl/en/ 
4 http://biobank.medunigraz.at/en/ 
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Appendix 5. Experts involved in interviews and informal 
discussions 
Jaana Ahlamaa, Medaffcon 
Johanna Arola, Finnish Biobank 
Klaus Breitholtz, Genevia 
Henrik Edgren, MediSapiens 
Päivi Eriksson, University of Eastern Finland 
Jari Forsström, Abomics 
Merja Auvinen, Diagfactor 
Jarmo Hahl, Medaffcon 
Kari Harno, University of Eastern Finland 
Kirsi Heikola, Novartis 
Reini Hurme, Zora Biosciences 
Pekka Ihalmo, Janssen-Cilag  
Johanna Hemdahl, Boehringer-Ingelheim 
Lila Kallio, Auria Biobank 
Antti Karlsson, Auria Biobank 
Jarmo Kaukua, Boehringer-Ingelheim 
Ossi Koskinen, Lääkärikeskus Aava 
Ilkka Kunnamo, Duodecim 
Kalle Kuusisto, Lähitapiola 
Marika Laaksonen, Fazer 
Ossi Laukkanen, Mehiläinen 
Tatu Laurila, Novartis 
Joel Lehikoinen, Kaiku Health 
Anne Lehtonen, AbbVie 
Tommi Lehtonen, Blueprint Genetics 
Amy Levál, Janssen Nordic 
Anssi Linnakivi, Roche 
Pekka Luukkainen, Lähitapiola 
Kristina Hotakainen, Mehiläinen 
Christer Nordstedt, Orion 
Harri Okkonen, Quattro Folia 
Seppo Orsila, Modulight 
Arto Pakkalin, Bayer 
Jaakko Parkkinen, Pfizer 
Jukka Partanen, Finnish Red Cross Blood Service  
Eero Punkka, Helsinki Biobank 
Christophe Roos, Euformatics 
Ville Salaspuro, Mediconsult 
Jaana Santaholma, Novartis 
Tero Silvola, BC Platforms 
Jukka Suovanen, Odum 
Tuula Tiihonen, Sitra 
Ilpo Tolonen, Docrates 
Juha Tuominen, Terveystalo 
Ingmar Wester, Raisio 
Hanna Viertiö-Oja, GE Healthcare 
Tom Wiklund, Docrates 
Petteri Viljanen, BCB Medical 
Arho Virkki, Turku University Hospital 
Maija Wolf, Medaffcon 
Arto Vuori, National Institute for Health and Welfare (THL) 
Anneli Vuorinen, Crown CRO 
Tero Ylisaukko-Oja, MedEngine 
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Appendix 6.  Interview questions 
Tentative interview questions (list adapted case-by-case for the interviewed organisation). 
Understanding Company 
Customers, products and price? 
Who are your main competitors or partners? 
What is your strategic direction and timeline for growth?  
What geographical areas are you planning to operate in? 
How do you market your products or services? 
What is your core IPR/IP? 
What is the role of scientific research or research collaboration in your Company? 
Value Chain 
How do you define the value chain in this area now and in the future? 
What is your Company’s position in the value chain? 
How do you see the market size in the future? 
Is the market formation dependent on public or private sector? 
Are there sufficient industrial actors in Finland? What is missing? 
Is there enough knowledge transfer between users and industry? What about science and 
industry? 
What needs and assets does your Company have for growth in precision medicine? 
 
Health Data 
Do you or are you planning to exploit personal health data and/or genome data? 
Which data is exploited and how  (e.g.  in R&D,  as part of final product, …)? 
How do you access (or plan to access) the data it needs? 
Which are the main obstacles currently in accessing data (legal, IT, permission process,  
competence..) 
Do you expect to benefit from the planned legislation on the secondary use of health and  
wellness data? How? 
What partnerships do you need for exploitation of health data (clinical, biobanks,  
research organisations…)? 
Do you have any plans for the analysis of data, or data enrichment? 
 
What kind of trends are foreseen in 3-5 years related to health data exploitation? 
 
FinnGen 
How would you understand 'Finnish precision medicine platform'? 
Importance of FinnGen platform for future business development 
What stumbling blocks or showstoppers can be foreseen? 
What competence and type of resource will be needed? 
How should the Finnish ecosystem be formed and strengthened? 
How should FinnGen be utilized? 
 
 
